Next Article in Journal
Selective Activation of CNS and Reference PPARGC1A Promoters Is Associated with Distinct Gene Programs Relevant for Neurodegenerative Diseases
Next Article in Special Issue
Design and In Vitro Evaluation of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, and Guanidine-Bridged Nucleic Acids
Previous Article in Journal
The Long Linker Region of Telomere-Binding Protein TRF2 Is Responsible for Interactions with Lamins
Previous Article in Special Issue
Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 7
10.3390/ijms22073295
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Recent Advances in Oligonucleotide Therapeutics in Oncology

by
Haoyu Xiong
1,
Rakesh N. Veedu
2,3 and
Sarah D. Diermeier
1,*
1
Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand
2
Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth 6150, Australia
3
Perron Institute for Neurological and Translational Science, Perth 6009, Australia
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(7), 3295; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22073295
Submission received: 28 February 2021 / Revised: 18 March 2021 / Accepted: 20 March 2021 / Published: 24 March 2021
(This article belongs to the Special Issue Precision Nucleic Acid Therapeutics)
Browse Figures
Versions Notes

Abstract

:
Cancer is one of the leading causes of death worldwide. Conventional therapies, including surgery, radiation, and chemotherapy have achieved increased survival rates for many types of cancer over the past decades. However, cancer recurrence and/or metastasis to distant organs remain major challenges, resulting in a large, unmet clinical need. Oligonucleotide therapeutics, which include antisense oligonucleotides, small interfering RNAs, and aptamers, show promising clinical outcomes for disease indications such as Duchenne muscular dystrophy, familial amyloid neuropathies, and macular degeneration. While no approved oligonucleotide drug currently exists for any type of cancer, results obtained in preclinical studies and clinical trials are encouraging. Here, we provide an overview of recent developments in the field of oligonucleotide therapeutics in oncology, review current clinical trials, and discuss associated challenges.

1. Introduction

According to the Global Cancer Statistics 2018, there were more than 18 million new cancer cases and 9.6 million deaths caused by cancer in 2018 [1]. Cancer incidence and mortality are growing rapidly throughout the world [1]. While lung, breast, prostate, and colorectal cancers show the highest incidence rates (11.6%, 11.6%, 7.1%, and 6.1%, respectively), lung, colorectal, stomach, and liver cancers are the deadliest cancers (18.4%, 9.2%, 8.2%, and 8.2%, respectively) [1]. The direct cost of cancer was estimated to be $1.16 trillion (USD) globally in 2010 [2]. According to US statistics, the cost for cancer was around 125 billion (USD) in 2010 and is estimated to rise to 158 billion (USD) in 2020 [3]. Conventional treatments for cancer, such as surgery to physically remove cancer tissues and metastases, radiation therapy to damage cancer cells under high energy waves, and chemotherapy therapy utilizing systemic cytotoxic drugs, have significantly improved cancer survival rates. However, the current standard of care for many types of cancer fails to address cancer recurrence and/or metastasis [4,5]. Moreover, conventional therapies are often accompanied by serious adverse effects such as systemic toxicity and multiple drug resistance [6,7].
Recent research into immune checkpoints and intrinsic mechanisms of cancer growth resulted in the development of targeted therapies including small molecule inhibitors and monoclonal antibodies as well as cell and immunotherapies, including checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy [7]. Checkpoint inhibitors such as PD-1 and PD-L1 demonstrate significant improvements in the clinic in some types of cancer, but their benefits are limited by fast post-therapy resistance and intrinsic absence of tumor neoantigens to enable blockade, rendering them ineffective for many patients [8,9]. CAR T-cell therapy requires functional tumor-specific antigens on the cell surface of cancer cells to enable targeting, and lack of these challenge the therapeutic purpose of CAR T-cell therapy, especially in solid tumors, which often do not express such antigens and show a 9% overall response rate [10,11,12]. Targeted therapy aims to inhibit cancer cell growth by blocking molecular targets essential for cell growth and tumorigenesis [13]. Many targeted drugs such as anti-EGFR agents and anti-VEGF/VEGFR agents have been approved for cancer treatments, but limitations include rapidly developing resistance and serious adverse effects [14,15]. While both conventional and newly developed treatments have significantly improved cancer survival rates, cancer recurrence and drug resistance remain challenging and indicate the urgent need for new therapeutic strategies.
Oligonucleotide therapeutics are an emerging drug modality, which consists of modified or unmodified short nucleic acid molecules, and includes antisense oligonucleotides (ASOs), small interfering RNA (siRNAs), microRNA (miRNAs), aptamers, and DNAzymes [16]. The mechanism of action of oligonucleotide therapeutics mainly relies on Watson–Crick base pairing to targeted mRNAs, resulting in either gene silencing, a steric block, or altered splicing patterns, with the exception of aptamers, which recognize their targets by their three-dimensional structures [16,17,18,19]. Currently, 13 oligonucleotide therapeutics have been granted new drug approval (NDA) by the U.S. Food and Drug Administration (FDA) for several different indications (Table 1) [20]. The underlying molecular mechanism is similar for all of these indications: a single gene mutation is responsible for these diseases. The approved oligonucleotide therapeutics act via a variety of different mechanisms correcting the affected gene, such as by blocking translation (fomivirsen, the first approved oligonucleotide drug but withdrawn due to safety issues), RNase H dependent degradation (mipomirsen, inotersen and volanesorsen), splicing modulation (eteplirsen, nusinersen, golodirsen, milasen, and casimersen), siRNA dependent degradation (patisiran and givosiran), aptamer binding and blocking (pegaptanib), and aptamer binding and activating (defibrotide) (Table 1) [20]. Defibrotide is different from other approved therapeutics as it consists of a mixture of single-stranded and double-stranded phosphodiester oligonucleotides, which act as aptamers to activate adenosine receptor and plasma membranes of vascular endothelial cells [21].
Oligonucleotide therapeutics have been investigated as cancer treatments for decades with promising in vitro outcomes and many have been tested in clinical trials [22]. However, there are currently no approved oligonucleotide therapeutics in oncology yet. Three ASO drugs were granted orphan drug designation (oblimersen for chronic lymphocytic leukemia, PNT2258 for diffuse large B-cell lymphoma, and cobomarsen for mycosis fungoides type cutaneous T-Cell lymphoma). Most oligonucleotide therapeutics for cancer are still in clinical phase 1 or 2. Currently (as of 01/01/2021), a total of 229 clinical trials investigating 60 oligonucleotide drugs in oncology are registered on ClinicalTrials.gov. Of these, 195 are using ASOs as intervention, 17 trials for siRNAs, seven trials for miRNAs, nine trials for aptamers, and one trial for DNAzymes (Figure 1a; Table 2). There are currently 15 oligonucleotide therapeutics in phase 2/3 or phase 3 trials (all for ASOs) (Figure 1b). In this review, we summarize current clinical trials of oligonucleotide therapeutics for cancer. We further discuss potential reasons for previous failures, new developments in the field, and future directions.

2. Types of Oligonucleotide Therapeutics

Currently, oligonucleotide therapeutics investigated in clinical trials include ASOs, siRNAs, miRNAs, aptamers, and DNAzymes. Their mechanisms of action differ, resulting in the correction of either abnormal expression or splicing patterns (Figure 2). Endocytosis is the main pathway for oligonucleotides to enter cells and various endocytic pathways are involved in the internalization of oligonucleotides [23]. Oligonucleotides can remain trapped in late endosomes, multivesicular bodies, and lysosomes, with a limited number being released from these endomembrane compartments to the cytoplasm and nucleus to enable their function [24]. Chemical modifications, conjugates and nanocarriers aid in overcoming such endosomal barriers [24]. For instance, different types of small molecules and anionic polymer conjugates are used to alter membrane stability of endosomes to release oligonucleotides [24].

2.1. Antisense Oligonucleotides (ASOs)

ASOs are small single-stranded deoxyribonucleotides (~12–30 nt) that specifically bind target RNAs through Watson–Crick base pairing [25,26]. Unmodified ASOs contains phosphodiester backbones, which create challenges for cellular uptake and are easily degraded by endogenous nucleases [22,27,28]. Their blood circulating half-life is comparably short (less than 5 min) due to fast nuclease degradation and low affinity to plasma proteins [25,26,29,30]. Thus, the phosphodiester backbone is usually chemically modified to increase cellular uptake and endonuclease resistance (Figure 3) [31].
There are three generations of modified ASOs. First generation ASOs carry phosphorothioate (PS) backbones, where a non-bridging oxygen atom is replaced by a sulfur group, increasing resistance to nuclease degradation [25]. However, the affinity to target mRNAs is slightly reduced due to a decreased melting temperature of the PS ASO-mRNA complex [25,26]. This modification also increases the sequence length-dependent binding affinity to plasma proteins, which improves the blood circulating half-life in return, while toxicity is increased at high concentrations [32,33,34]. PS ASOs are taken up readily by mammalian cells with fast growing cells showing higher uptake efficiency compared to slow growing cells [35]. PS ASOs bind to cell surface proteins and enter cells through different forms of endocytosis including surface receptor mediated pathways and micropinocytosis [35]. Further, PS modifications also increase intracellular protein binding such as to nucleolin, which aids in the enrichment of PS ASO in the nucleus [27]. The non-bridging oxygen atom can also be replaced by a methyl or amine group, to generate methyl-phosphonate ASOs (MP ASOs) and N3′-P5′ phosphoramidates ASOs (N3′-P5′ NP ASOs), respectively (Figure 3) [36]. While MP ASOs show higher nuclease stability than PS ASOs, their reduced overall charge limit cellular uptake and their protein binding ability, leading to shorter blood circulating half-life compared to PS ASOs [30]. N3′-P5′ NP ASOs obtain increased affinity to target sequences and increased resistance to nuclease degradation, but exhibit low protein binding ability and are easy to degrade under acidic conditions, which may exist in solid tumors [25,26,37,38,39]. As one application of ASOs is to degrade target RNA by recruiting RNAse H, it should be noted that only the sulfur backbone modification of first generation ASOs retains RNAse H cleavage activity [40]. RNAse H is an endonuclease that can bind to RNA/DNA hybrids, RNA duplexes and DNA duplexes, but it only degrades RNA in RNA/DNA hybrids via a hydrolytic reaction [25,26,40,41]. Fomivirsen, the first FDA approved ASO, is an example of a PS ASO in the clinic [42].
Additional chemical modifications of ASOs further increase the binding affinity to target RNAs as well as nuclease resistance [43]. These developments include modifications at the 2′ position of the sugar moiety, replacing the hydroxyl group with methyl or methoxyethyl groups to form sugar-modified analogues such as 2′-O-methyl (2′-OMe) and 2′-O-methoxyethyl (2′-MOE) (Figure 3) [43]. These modifications also increase the toxicity [43]. ASOs with fully modified ribose backbones cannot undergo RNAse H dependent degradation [44]. Therefore, second generation PS ASOs intended for target degradation retain PS-modified deoxynucleotides in the central region to allow for RNase H cleavage, with 2′-MOE-PS and other sugar modifications at both 3′ and 5′ ends, resulting in a gapmer structure [45]. ASOs with fully modified ribose backbones can be used as steric blocking ASOs or splicing modulators [27]. Steric blocking ASOs bind to target RNA with high affinity, which can interfere with the interaction between target RNA and other molecules (RNA, DNA and proteins) important for its function [46]. Mipomersen and inotersen are second generation 2′-MOE-PS ASOs with 5′-methyl pyrimidines at both 3′ and 5′ ends [46].
Third generation ASOs utilize various modifications to further decrease nuclease degradation and increase target binding ability [47]. Locked nucleic acids (LNAs), in which the 2′-oxygen and the 4′-carbon on the same ribose are connected through a methylene bridge, show increased stability through increased melting temperatures (Figure 3) [48,49]. Similar to second generation ASOs, fully modified LNAs cannot activate RNase H cleavage [48,49]. To enable the RNA cleavage function, a gapmer structure with a central DNA region and LNAs at both ends is required [48]. LNAs have been reported to be associated with high liver toxicity, while introducing unmodified oligonucleotides in the gapmer structure was reported to reduce liver toxicity [50]. Constrained methyl- and ethyl-bridges in constrained methoxyethyl (cMOE) and constrained ethyl (cEt) oligonucleotides further reduce toxicity compared to LNA oligonucleotides [50]. Phosphorodiamidate morpholino oligomers (PMOs) and peptide nucleic acids (PNAs) are the other two most commonly used third-generation ASO [51]. In PMOs, a morpholine moiety connected through methylene phosphorodiamidate replaces the ribose (Figure 3). PMOs are frequently used to block mRNA translation [51]. In PNAs, which are frequently used in blocking transcription or translation, the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone, which leads to an increase in melting temperature (Tm) and high affinity to DNA or RNA [52]. Since PMOs and PNAs are neutrally charged molecules, they do not show high levels of plasma protein binding and are rapidly cleared via renal pathways [27]. Currently, there are no third generation ASO that are approved by the FDA.
First generation ASOs (fully PS modified) are not widely used at this stage as ASOs with PS modifications usually utilize a gapmer structure with second or third generation modifications on the 5′ and 3′ ends. Such modifications increase target sequence binding affinity, increase resistance to nuclease, and reduce immune activation. However, some of these more recently developed modifications exhibit higher toxicity (Table 3). Further, ASOs are often conjugated with various moieties including cholesterol, peptides, sugar and aptamers for the purpose of either specific targeting or cell penetration [27]. An example is the N-acetylgalactosamine (GalNAc) conjugate, which binds to the asialoglycoprotein receptor (ASGPR) highly expressed in hepatocytes and leads to endocytosis of such modified ASOs [53]. Furthermore, polymer conjugates, such as cationic polymers or polyethylene glycol (PEG), improve resistance to nuclease degradation and increase cellular uptake [54].

2.2. CpG Oligonucleotides

CpG oligonucleotides are short single-stranded oligodeoxynucleotides containing CpG motifs and are used in the immunomodulatory response to stimulate Toll-like receptor 9 (TLR9) [55]. TLR9 plays a role in the recognition of pathogen molecules and the activation of the innate immune response [55,56]. The human Toll-like receptor family contains ten members, which recognize different types of molecules [55]. TLR9 subfamilies are mainly expressed in B cells and plasmacytoid dendritic cells (pDCs) and recognize unmethylated CpG-DNA [55]. CpG motifs interact with TLR9 and activate B cells and pDCs, which boosts the immune response, leading to proliferation and differentiation of these cells and cytokine secretion, and the activation of genes involved in inflammatory responses [57,58,59]. In response to chemotherapy, TLR9 acts as a tumor sensor by recognizing tumor released DNA, triggering an immune response and activating tumor-specific cytotoxic T lymphocytes (CTLs) [57]. This principle is exploited in the application of synthetic CpG oligonucleotides to enhance TLR9 related immune responses [57,58,59]. Currently, there are three types of CpG oligonucleotides being developed and tested in clinical trials, based on the types of immune cells activated: class A, B, and C. Class A CpG oligonucleotides (including ODN-2216) contain a single CpG motif and induce IFN-α secretion from pDCs [60]. Class B CpG oligonucleotides (including CpG-7909, IMO-2055, and 1018-ISS) contain multiple CpG motifs and stimulate B-cell activation and pDC maturation [61]. Class C CpG oligonucleotides (including SD-101) combine the characteristics of both class A and B and can induce high levels of IL-12 secretion from pDCs [62]. CpG oligonucleotides are being tested both as monotherapy and immunotherapeutic adjuvants in combination with chemotherapy, radiotherapy, and targeted therapy [63].

2.3. miRNAs

miRNAs are short (~18–25 nt) single stranded non-coding RNAs that contain complementary sequences to one or more mRNAs, usually within the 3′-UTR [64]. They play an important function in post-transcriptional gene repression [64]. miRNA genes are transcribed in the nucleus by RNA polymerase II to form pri-miRNAs, which are cleaved by RNase III to form pre-miRNAs and are exported into the cytoplasm [65,66]. The pre-miRNAs are further processed by Dicer to form double stranded miRNAs, which are components of the RNA-induced silencing complex (RISC) [65].
Dysregulated expression of many miRNAs is found in various types of cancers due to altered miRNA gene copy numbers, changes to the epigenetic status of miRNA genes, or aberrant transcription or synthesis [67]. Different types of cancers were shown to have different miRNA signatures compared to normal tissues [68]. Moreover, specific miRNA signatures are associated with drug resistance, such as elevated miR-214 levels in recurrent cisplatin-resistant patients [69]. Therefore, miRNAs and in particular circulating miRNAs may have potential as cancer biomarkers or indicators of drug sensitivity. Most current clinical trials on miRNAs (101 of 108) aim to discover novel cancer biomarkers or indicators of drug sensitivity (Supplementary Materials, miRNA screening). Around 30% of the trials investigate miRNAs that have previously been identified to show altered expression in cancer and the remaining 70% intend to find novel miRNA signatures for diagnostic use (Supplementary Materials, miRNA screening). Early studies using naked forms of miRNAs were often unsuccessful due to challenges with degradation and cell delivery [70]. Structure modifications and delivery systems including nanoparticles may aid in overcoming these obstacles [70].

2.4. siRNAs

SiRNAs are 20–25 bp long double stranded RNAs, which are produced by Dicer from long dsRNAs and small hairpin RNAs [71]. Similar to miRNAs, siRNAs work in complex with RISC to post-transcriptionally silence target gene expressions [71]. siRNAs have been extensively used in RNA interference and represent another strategy to modulate overexpressed mRNAs in cancer [72]. siRNAs are cleaved by endonucleases at pyrimidines and by exonucleases at both ends [73]. Chemical alterations of siRNAs such as non-consecutive 2′-OMe modifications and PS modifications enhance nuclease resistance and selectivity of RISC loading without inhibiting RNAi efficiency [74]. siRNAs are usually delivered using lipid nanoparticles, which protect the encapsulated siRNAs and improves cellular uptake by macropinocytosis [35]. Moreover, various types of nanoparticles and conjugates have been developed for safe and targeted delivery of siRNAs [75]. These either target specific cell surface receptors, increase non-specific interactions with cell membranes, or assist with endocytosis [73]. Currently, most siRNAs in clinical trials are focused on genetic diseases.

2.5. Aptamers

Aptamer oligonucleotides are single-stranded DNA or RNA oligonucleotides that bind targets with high affinity based on their three-dimensional structures [17]. Aptamer oligonucleotides are screened using the systematic evolution of ligands by exponential enrichment (SELEX) technology from a synthetic oligonucleotide pool against a target (either RNA or protein) [76]. Aptamers are often used as a drug delivery system for chemotherapeutics, RNA therapeutics and nanoparticles containing drugs by specifically binding to cell- and tumor-type specific cell surface receptors [44]. Aptamers can also act as therapeutics by blocking essential interactions between the target and other molecules [44]. In addition, aptamers can be used as antagonists of immune checkpoints such as PD-1 and PD-L1 to remodel immune responses, or as agonists of costimulatory receptors to activate related pathways [77]. Moreover, aptamers have been used in cancer diagnosis and detection due to their high affinity to targets resulting from the SELEX selection process [78]. Aptamers are selected to target cancer surface markers such as nucleolin and MUC1 or metastatic cell lines to detect various types of cancer or cancer metastasis [78]. Unmodified DNA/RNA aptamers are nuclease sensitive with poor serum stability in vivo [79]. Modifications on the sugar ring and phosphodiester linkage have been shown to increase nuclease resistance. Moreover, modifications on the 5′ and 3′ end (end capping) and the utilization of an L-enantiomer form of nucleic acids provide additional options to protect aptamers from nuclease degradation [80]. To increase the half-life in systemic circulation, attachments on the 5′ end including cholesterol, dialkyl lipids and PEG reduce renal filtration and prolong circulation time [80]. While showing promising results in vitro, most aptamers currently in preclinical development as cancer therapeutics target cell surface receptors including CD28, CD40, and 4-1BB (CD137), and have not entered clinical trials yet [81].

2.6. DNAzymes

DNAzymes are catalytically active DNA oligonucleotides that have the potential to cleave RNA and to ligate and phosphorylate DNA or RNA [82,83]. Currently, DNAzymes are not found in nature but are generated using in vitro selection strategies (SELEX) [83]. DNAzymes that cleave RNAs are the most well studied type of DNAzymes in cancer research due to their potential to silence genes [84]. These RNA-cleavage DNAzymes consist of a catalytic core and two arms, which bind and recognize specific RNA sequence through Watson–Crick base pairing [85]. Two widely studied DNAzymes are 10-23 DNAzymes and 8-17 DNAzymes [86]. The efficiency of the RNA cleavage relies on the metal ion in the core [84]. DNAzymes also face the challenge of nuclease degradation. Chemical modifications such as phosphorothioate (PS) and 2′-O-methoxyethyl (2′-MOe) and conjugates including polyamines and peptides significantly increase the stability of DNAzymes against nucleases in vivo [85,87]. Efficient cellular delivery is another barrier for the application of DNAzymes and nanocarriers such as lipid nanoparticles and cationic polymers can improve uptake [88]. Despite promising outcomes in vitro and in animal models, only one clinical trial has been completed for DNAzymes in oncology thus far [84].

3. Clinical Trials for Oligonucleotide Therapeutics in Oncology

For the purpose of this review, we summarized clinical trials registered on ClinicalTrials.gov by searching terms including oligonucleotide, antisense oligonucleotide (ASO), small interfering RNA (siRNA), microRNA (miRNA), aptamer, and DNAzyme in the intervention/treatment section with diseases limited to cancer/neoplasm/tumor/carcinoma. We also investigated pipelines and products of some of the major nucleic acid therapeutics companies including Arrowhead Pharmaceuticals, Akcea Therapeutics, Alnylam Pharmaceuticals, BioNTech, CureVac, Gotham Therapeutics, Gradalis, Ionis Pharmaceuticals, Moderna, and Quark Pharmaceuticals. We retrieved a total of 229 clinical trials for oligonucleotide therapeutics in oncology.

3.1. Clinical Trials for ASOs in Oncology

There are 120 trials completed thus far, which consist of 44 phase 1 trials, 23 phase 1/2 trials, 44 phase 2 trials, and nine phase 3 trials. According to ClinicalTrials.gov, there are currently 35 terminated trials, five withdrawn, one suspended, six with unknown status and 27 ongoing trials (Supplementary Materials, ASOs). Here, we summarize landmark studies and the most recent trials for ASOs in oncology since 1993.

3.1.1. First ASO in Cancer Clinical Trials, G4460

The first clinical trial of ASOs in oncology registered on ClinicalTrials.gov is a phase 2 trial launched in 1993, investigating G4460 (a PS ASO developed by Genta Incorporated) in chronic myelogenous leukemia (clinical trial identifier: NCT00002592). G4460 binds to codon sequences 2–9 of the CMYB mRNA and triggers RNAse H dependent degradation [89]. CMYB is a proto-oncogene that encodes a transcription regulator essential for cell proliferation, differentiation, and apoptosis [90,91]. Over-expression of c-Myb leads to increased proliferation and reduced differentiation in many types of cancers including leukemias and breast cancers [91]. A preclinical experiment indicated that the ASO inhibits proliferation of the human leukemia cell line HL-60 by 75%–80% [92,93]. In this trial, tumor cells were removed from bone marrow transplants by treating the bone marrow with G4460. Results were not disclosed. However, a phase 1 trial by the same investigator, Selina M. Luger, investigates G4460 in other hematologic malignancies, using a similar method as NCT00002592 (clinical trial identifier: NCT00780052). A publication for NCT00780052 reports that CMYB mRNA levels were undetectable in eight out of 18 (44.4%) of the treated bone marrow samples and major cytogenetic responses were found in six of 14 (42.9%) patients with ASO treated bone marrow transplants [94]. Clinical efficacy of the ASO could not be evaluated in this phase 1 trial, but the study demonstrated the feasibility of transplanting ASO treated bone marrow [94].

3.1.2. ASOs in Phase 3 Trials

There are 15 phase 2/3 or phase 3 trials, 10 were completed, three were terminated, one was withdrawn and two are of unknown status (Supplementary Materials, ASOs). These trials are for the ASO drugs Genasense (targeting BCL2, eight trials), ISIS-3521 (targeting PKCα, two trials), AP-120009 (targeting TGFB2, one trial) and OGX-011 (targeting ApoJ, four trials).

B-Cell Lymphoma 2 (BCL2)

Since 1997, 44 clinical trials have been performed on Genasense (developed by Genta Incorporated) in various types of cancers such as melanoma, leukemia, multiple myeloma, plasma cell cancer, and lung cancer. Moreover, 17 trials were launched by Genta (Supplementary Materials). Genasense, also named oblimersen and G3139, is a PS ASO targeting the first six codons of BCL2 mRNA and triggering RNase H dependent degradation [95]. B-cell lymphoma 2 (BCL2) is a 26 kDa protein that maintains the integrity of the outer mitochondrial membrane [96]. BCL2 regulates the mitochondrial apoptosis pathway and overexpression leads to escape from apoptosis in cancer cells [97,98]. Genasense obtained orphan drug designation for chronic lymphocytic leukemia (CLL) in 2001 [95]. Of eight initiated phase 3 trials, five were completed. However, Genasense was not approved because of unsatisfactory primary endpoint outcomes in all phase 3 trials, as overall survival (OS) and progression-free survival (PFS) did not increase with statistical significance. The secondary endpoint was reached for NCT00024440, which investigated fludarabine plus cyclophosphamide alone vs. combined with Genasense in CLL, showing complete or partial response (p = 0.025) in the Genasense combination group [99]. Three trials investigating different combinations of chemotherapy with Genasense were terminated since the production of Genasense ceased (NCT00064259, NCT00736450, and NCT01200342).
There are several phase 1 or 2 trials investigating different ASOs targeting BCL2, including BP1002 developed by Bio-Path (NCT04072458), PNT2258 developed by ProNAi Therapeutics (NCT01191775, NCT01733238, NCT02226965), and SPC2996 developed by Santaris Pharma (NCT00285103). BP1002 is a liposome encapsulated neutral P-ethoxy-ASO that blocks the translation of BCL2 mRNA. PNT2258 is also a liposome encapsulated ASO but targets the BCL2 protomer and inhibits transcription by DNA interference. A phase 1 trial confirmed its safety [100]. A phase 2 trial of PNT2258 (NCT01733238) indicated a single-agent response rate of 8.1% in diffuse large B-cell lymphoma (DLBCL) patients, prompting ProNAi Therapeutics to suspended further development due to low efficacy, even though it was granted orphan drug designation for treating DLBCL [101]. SPC2996 is a gapmer LNA targeting codons 1–6 of the BCL2 mRNA and differs in just three nucleotides from the Genasense sequence [102]. The phase 1/2 trial of SPC2996 (NCT00285103) indicated that 40% of the patients underwent painful inflammatory reactions and failed to prove significant single-agent efficacy to inhibit BCL2 expression, similar to Genasense [102].
The failure of ASOs to target BCL2 may be due to its long protein half-life, which reduces the continuing inhibition of BCL2 activity. The focus of BCL2 research has since shifted to inhibit domains of the BCL2 protein [103]. In 2016, a small molecule inhibitor targeting the BH3 domain of BCL2, venetoclax, was approved by the FDA due to a significant response rate (>70%) in a phase 2 trial [104].

Protein Kinase C Alpha (PKCα)

Protein kinase C alpha (PKCα) is a serine/threonine kinase that is involved in diverse cellular signaling pathways [25,26,105,106]. Overexpression of PKCα and the PKC family overall increases cancer cell proliferation and has been shown to correlate with progression of several types of cancer, such as breast and ovarian cancers [106,107]. ISIS-3521, also known as LY900003, aprinocarsen and Affinitak, is a PS ASO initially developed by Ionis Pharmaceuticals and licensed to Eli Lilly for co-development, that targets the 3′ UTR of PKCA mRNA, resulting in the inhibition of PKCα protein synthesis [108]. Phase 1 and 2 trials of ISIS-3521 in various cancer types demonstrated mild to moderate toxicity and low single-agent activity [108]. Combinations of chemotherapy and ISIS-3521 in phase 2 trials in lung cancer showed acceptable response rates, resulting in the initiation of two phase 3 combination trials [108,109]. ISIS-3521 received Fast Track Designation, but the phase 3 trials on non-small cell lung cancer showed that ISIS-3521 combined with chemotherapy did not increase OS and failed other clinical measures, including low response rates and increased toxicity (p < 0.0001). The ASO drug was thus not approved, and Eli Lilly announced no further development [110,111].

Transforming Growth Factor Beta (TGFβ)

Transforming growth factor beta (TGFβ) is a secreted cytokine that has three isoforms, β1, β2, and β3, and plays important roles in embryonic development, cell growth and differentiation [112]. Overexpression of TGFβ leads to increased cell proliferation, invasion and metastasis, and has been observed in various cancers including glioma, pancreatic and colorectal cancers [113,114]. AP-120009, also named trabedersen and OT-101, is a PS ASO developed by Antisense Pharma (now Isarna Therapeutics), that targets TGFB2 mRNA and induces RNAse H dependent degradation [115]. Preclinical trials indicated that AP-120009 significantly reduces TGFβ2 expression in cancer and exhibited low toxicity in animal models [25,26,116,117]. Phase 1 and 2 trials demonstrated a favorable safety profile for AP-120009 and extended patient survival, especially for anaplastic astrocytoma patients with two complete responses [116]. A phase 2b trial for AP-120009 further indicated significant cancer control rates (drug response) in the anaplastic astrocytoma (AA) subgroup with AP-120009 compared to AA patients receiving chemotherapy (p = 0.0032) [118]. The FDA granted orphan drug designation for AP-120009 in 2002 for diffuse intrinsic pontine glioma (DIPG) and in 2009 for pancreatic cancer [119]. The phase 3 trial of AP-120009 on anaplastic astrocytoma and glioblastoma patients was terminated by Isarna Therapeutics. Further development of AP-120009 is still ongoing and Mateon Therapeutics/Oncotelic announced in 2020 that a combination of AP-120009 and interleukin-2 (IL-2) will be tested in phase 1 trials.

Apolipoprotein J (ApoJ)

Clusterin, or apolipoprotein J (ApoJ), is a multifunctional glycoprotein acting as a cell-aggregating factor and playing an important role in cell adhesion and programmed cell death [120]. Studies showed that it is overexpressed in metastatic cancer cells including colon, bladder, and hepatocellular cancer [121]. The overexpression of ApoJ increases cell migration and assists cancer metastasis [121]. In addition, overexpression of ApoJ reduces TNFα-mediated apoptosis and is associated with the development of drug resistance [122]. OGX-011, a 2′-MOE PS ASO co-developed by Ionis Pharmaceuticals and OncoGenex Pharmaceuticals, targets the translation-initiation site of ApoJ [123]. OGX-011 received Fast Track Designation, but two of its phase 3 trials failed [123]. The phase 3 trials NCT01578655 and NCT01188187 investigated the combination of OGX-011 with abazitaxel/docetaxel and prednisone versus chemotherapy alone in metastatic castration-resistant prostate cancer. No difference of OS was found when comparing chemotherapy + OGX-011 with chemotherapy alone in both NCT01578655 and NCT01188187 [123,124,125]. Serious adverse events were detected in both patient cohorts, in 49% and 42% of patients in each group in NCT01578655, and in 43% and 36% in NCT01188187 [123].

3.1.3. Additional ASOs in Phase 2 Trials

There are additional ASOs that have reached phase 2 trials, with AEG35156 (XIAP), danvatirsen (STAT3), apatorsen (HSP27), ISIS 2503 (HRAS), ISIS 183750 (EIF4E) and cenersen (P53) making up the largest number of trials [25]. While all preclinical studies provided significant anti-tumor responses, the clinical trials have various levels of responses in patients. Three ASOs that have been tested in several phase 2 trials are discussed below.

X-Linked Inhibitor of Apoptosis (XIAP)

XIAP encodes the X-linked inhibitor of apoptosis protein, which directly binds caspases to inhibit apoptosis [126]. XIAP is overexpressed in a variety of cancers and drives resistance to chemotherapeutics and targeted drugs [126]. AEG35156 is a PS ASO developed by Aegera Pharmaceuticals that triggers RNase H dependent degradation of XIAP mRNA. In a phase 2 trial combined with sorafenib in advanced hepatocellular cancer, AEG35156 showed higher objective response rates (ORRs) in combination groups compared to the sorafenib only group and was accompanied by few serious adverse events (1 in 32) [127].

Signal Transducer and Activator of Transcription 3 (STAT3)

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that participates in cellular proliferation, migration, invasion and survival [128]. Activation of STAT3 has been found in various cancer types and inhibition of STAT3 leads to decreased proliferation in cancer [129]. Danvatirsen (AZD9150, ISIS STAT3Rx) is a 16 nt cEt modified PS ASO with cEt nucleosides at both 5′ and 3′ ends developed by Ionis Pharmaceuticals that sterically blocks translation of STAT3 mRNA [130]. Danvatirsen demonstrated promising anti-tumor activity in cell and animal models [129,131]. A phase 1b trial (NCT01563302) demonstrated two complete responses and two partial responses in DLBCL patients (total 30) [132]. Phase 2 trials are currently recruiting.

Heat Shock Protein 27 (HSP27)

Heat shock protein 27 (HSP27) is a 27-kDa protein induced by stress such as heat, hyperthermia and chemotherapy. HSP27 acts as a protein chaperone, is involved in the inhibition of apoptosis and is ubiquitously expressed [133]. HSP27 is overexpressed in many cancer types and associated with poor prognosis, cancer cell survival and drug resistance [134]. Apatorsen (OGX-427) is a 2′-MOE PS ASO developed by OncoGenex Pharmaceuticals and triggers HSP27 mRNA degradation via RNase H. Apatorsen inhibits the expression of HSP27 to increase the sensitivity of cancer cells to chemotherapy [135]. Preclinical experiments indicate that apatorsen combined with erlotinib inhibits growth of A549 xenografts significantly, leading to high apoptosis rates compared to controls [135]. However, three phase 2 trials (NCT01844817 for pancreatic cancer, NCT01829113 for non-squamous-non-small-cell lung cancer, NCT01120470 for prostate cancer) investigating apatorsen combined with chemotherapy did not significantly improve either PFS and OS (NCT01120470 and NCT01844817), or disease response (NCT01829113) in cancer patients without HSP27 level screening (p > 0.05) [136,137,138].
In summary, significant responses of ASOs as therapeutics in oncology were achieved in subgroups of patients in phase 3 trials for Genasense and trabedersen, and some responses were seen in AEG35156 and danvatirsen. Thus far, a number of phase 3 clinical trials of ASOs in cancer have not reached sufficient primary endpoints such as PFS and OS, suggesting that future trials may want to focus on determining the factors underlying the heterogeneous response to the drugs, specifically evaluating pre-screened subgroups of patients, and focusing on new targets. In addition, most ASOs that have completed phase 3 trials thus far are first generation ASOs (PS ASOs), with drawbacks including reduced affinity and specificity, which may contribute to somewhat low clinical efficacy in clinical trials [139]. Future clinical trials with second or third generation ASOs may lead to increased efficacy and improved PFS and/or OS.

3.2. CpG Oligonucleotides

Thus far, just one CpG oligonucleotide has completed phase 3 trials, CpG 7909. CpG 7909 (PF03512676) is a class B 24 nt agonist of TLR9 in B cells and pDCs [140]. Both phase 3 trials of CpG 7909 (PF03512676) in non-small-cell lung carcinoma showed no improvement of OS and increased adverse events over control groups [141,142,143]. Two additional CpG oligonucleotide therapeutics have completed phase 2 trials, IMO-2055 (EMD 1201081) and 1018 ISS, and a third, SD-101, completed phase 1 trials. The phase 2 trial on IMO-2055 (EMD 1201081) in combination with cetuximab (NCT01040832) showed acceptable toxicity in squamous cell cancer of the head and neck patients but low clinical efficacy (no significant improvement of PFS) compared to the control group on cetuximab alone [144]. 1018 ISS is a 22 bp unmethylated class B CpG PS oligodeoxynucleotide. A phase 2 trial (NCT00251394) in combination with rituximab for non-Hodgkin lymphoma showed an overall response rate of 32% with low toxicity [145]. For SD-101, the phase 1b trial combined with pembrolizumab in advanced melanoma showed that the combination is well tolerated and induced an ORR of 78% in patients without prior PD-1 treatment experience, but an ORR of 15% in patients with prior PD-1 treatment experience [146]. CpG oligonucleotides usually serve as adjuvants to improve the effects of chemotherapeutics or targeted therapy, and further evidence is needed for the use of CpG oligonucleotides as an immunologic adjuvant [63].

3.3. miRNAs

Two types of oligonucleotides are currently being used as miRNA therapeutics: miRNA mimetics to restore the levels of miRNAs downregulated in cancer, and antagomiRs to inhibit overexpressed miRNAs [147] (Figure 2). Thus far, six clinical trials have been investigating their potential as oncology drugs. Of these, three were terminated and one withdrawn, leaving two phase 1 trials completed and one still recruiting patients. The termination of NCT01829971 and the withdrawal of NCT02862145 were due to frequent related serious adverse events reported by the investigators, and the other two terminated trials were due to business reasons and patients placed in other trials according to comments on ClinicalTrials.gov (Supplementary Materials, miRNA).
One phase 1 trial (NCT02580552) investigated cobomarsen (MRG-106), an LNA blocking MIR155 (associated with poor prognosis), in lymphoma and leukemia. In this phase 1 trial, patients showed acceptable toxicity and drug responses in all four patients recruited for intratumoral injection with decreased neoplastic cell density and depth [148]. The FDA granted Orphan Drug Designation to cobomarsen for mycosis fungoides type cutaneous T-cell lymphoma in 2017. In vitro studies indicate that depleted miR-16 levels can be restored with MIR16 mimetics in malignant pleural mesothelioma cell lines, which led to growth inhibition [149]. However, the phase 1 trial of TargomiRs (MIR16 based miRNA mimetic) showed low response rates (one in 22 patients) [149,150].
All miRNA therapeutics across indications are still in clinical trials with some positive outcomes thus far. Studies on miRNAs for cancer diagnosis have exponentially increased over the past 20 years and miRNA based diagnostic tools are being developed and tested by companies such as Rosetta Genomics, Interpace Diagnostics and Hummingbird Diagnostics [147].

3.4. siRNAs

Currently, there is one phase 2 trial recruiting patients using siRNAs as therapeutics in oncology. NCT01676259 is investigating siG12D-LODER, a novel biodegradable polymeric matrix containing an siRNA targeting mutated KRAS (KRAS G12X mutation) in advanced pancreatic cancer patients undergoing chemotherapy [151]. In this trial, siG12D-LODER is delivered directly into the solid tumor through implantation. The trial was scheduled to complete in June 2020, but the results have not yet been released. A phase 1 trial (NCT01188785) showed a decrease in tumor marker CA19-9 in 70% of the patients implanted with siG12D-LODER, but no difference in OS between all trial groups (different dosage of siG12D-LODER) [152]. As to other therapeutics developed targeting mutant KRAS, the FDA granted sotorasib, a KRAS G12C small molecule inhibitor priority review status in 2021 for the treatment of non–small cell lung cancer patients with KRAS G12C mutation. Most trials assessing siRNA drugs for cancer are currently in phase 1. However, some trials show promising initial responses. In NCT01158079, which tests a lipid nanoparticle containing two siRNAs targeting two genes (VEGF and kinesin spindle protein KSP) administered through intravenous infusion, a complete response was seen in one patient and disease stabilization for 1–1.5 years in several other patients [152,153]. In NCT02110563, which used siRNAs targeting the oncogene MYC, complete response was seen in one patient and tumor shrinkage was observed in several patients [154]. Similarly, NCT00672542, which utilized intradermal injection of siRNA transfected dendritic cells for melanoma patients resulted in one complete and one partial response (n = 5) [155].

3.5. Aptamers

There are nine trials for four aptamer drugs on ClinicalTrials.gov (six completed, one terminated and two with unknown status) (Supplementary Materials, Aptamers). Four trials investigate the drug AS1411, a DNA aptamer targeting nucleolin, with one phase 2 trial (NCT00740441) indicating limited response in one patient (FGFR2 and mTOR mutations) based on high levels of reduction in tumor diameter [156]. Three trials evaluated NOX-A12, an RNA aptamer that neutralizes CXCL12, a chemokine regulating the activity of CLL cells, with phase 2 trial NCT01486797 showing promising response rates (86%) [157,158]. A trial for the drug 68Ga-Sgc8, a DNA aptamer targeting protein tyrosine kinase-7 (PTK7) is used for diagnostic purposes in colorectal cancer (status: unknown). Lastly, a trial for the drug EYE001 (anti-VEGF pegylated aptamer) has not released any results yet.

3.6. DNAzymes

Thus far, just one trial for a DNAzyme in oncology is logged on ClinicalTrials.gov. NCT01449942 (Phase 1 and 2) utilized a DNAzyme to reduce the expression of Epstein-Barr virus—encoded latent membrane protein 1 (EBV-LMP1), which is an oncogenic protein in nasopharyngeal carcinoma [159]. A significant decline of Ktrans values, which indicates tumor blood flow and permeability, was found in the experimental group compared to the control group. The secondary endpoint parameters kep (the rate of contrast agent transfer to plasma) and ve (distribution volume of contrast agent) showed no significant difference between groups [159]. A phase 1 trial in 2010 (not registered on ClinicalTrials.gov) of the DNAzyme Dz13, which targets c-Jun, showed no serious adverse effects in patients with nodular basal-cell cancer, and c-Jun expression was decreased. However, there were no further clinical trials to confirm the efficacy of the treatment [160]. c-Jun is an important target of the Jun N-terminal kinase (JNK) signaling pathway, and several JNK inhibitors have been approved by the FDA [161]. Meanwhile, at least seven clinical trials were performed on the DNAzyme hgd40 (SB010, SB011, and SB012), which targets GATA3, a transcription factor highly mutated in more than 10% of breast cancers, in patients with severe allergic bronchial asthma, atopic dermatitis, and ulcerative colitis [162,163].
Thus far, ASOs are the most well-studied oligonucleotide therapeutics modality in clinical trials for oncology purposes, with the largest number of registered trials. Other nucleic acid drugs modalities such as miRNAs, siRNAs, aptamers, and DNAzymes are all at early stages of clinical trials in cancer, with promising responses in some patients.

4. Benefits of Oligonucleotide Therapeutics

Oligonucleotide therapeutics are able to target previously ‘undruggable’ targets such as RAS and MYC, which contain large protein-protein interaction surfaces and/or lack suitably deep protein pockets, providing new approaches for complex diseases [46,164]. The approval of 13 oligonucleotide therapeutics by the FDA demonstrates their potential in a range of indications. For oncology, there are three ASOs that have been granted orphan drug designation.
With research exploring the underlying molecular mechanisms of diseases, oligonucleotide therapeutics represent a straight-forward drug design approach compared to small molecules and other targeted therapeutics. In addition, oligonucleotides can be synthesized in a shorter time frame and at lower cost compared to chemotherapeutics and other types of targeted therapies [165]. Oligonucleotide therapeutics show high affinity to targets based on one dimensional sequence matches, suggesting simplicity in design compared to time consuming large scale computational searches, and do not require validation of tertiary protein domain matches like small molecule therapeutics [46,165,166,167]. The comparably simple structure and reproducible chemistry of oligonucleotide backbones result in known safety profiles, such as reduced activation of an immune response, which is ideal for the usage in combination therapy targeting different genes [168].
ASOs are the most frequently studied oligonucleotide therapeutics in clinical trials currently. Various types of administration can be used for ASOs to increase the number of relevant clinical applications [25]. Variation in biodistribution and bioactivity of ASOs is largely driven by their backbone chemistry, which can be improved or changed by structure modifications and linkage to delivery vectors [25]. In contrast, siRNA and miRNA therapeutics to trigger endogenous RISC-dependent RNA silencing require suitable vectors for delivery, such as liposomes [169]. Aptamers have potential to be used extensively in multiple ways in oncology, including as therapeutics, diagnostics, and drug delivery vectors.

5. Overcoming Challenges of Oligonucleotide Therapeutics

Though most clinical trials of oligonucleotide therapeutics did not show significantly improved PFS, complete or partial response have been observed in many patients mentioned as discussed above [166,167,170,171]. Below, we discuss several factors that may impact the therapeutic efficacy of oligonucleotide therapeutics in clinical trials and suggest pathways to overcome current challenges.

5.1. Drug Delivery Efficiency

Early clinical trials using unmodified or minimally modified oligonucleotide therapeutics (PS ASOs) faced challenges including efficiently delivering the drugs to cancer cells in the body [46]. Drugs need to overcome several barriers to successfully enter cells and avoid rapid clearance from circulation to exhibit therapeutic effects [24]. The review by Khvorova and Watts (2017) pointed out that applying these first-generation oligonucleotide therapeutics in trials may have been detrimental to the field [47]. Recent developments in nucleic acid chemistry and new modes of delivery seem to be able to overcome the delivery challenges earlier generation oligonucleotide therapeutics have faced, based on promising initial results indicating greatly improved clinical efficacy [47]. In addition to the second and third generation ASO backbone modifications discussed above, most types of oligonucleotides can be conjugated to small size molecules including lipids, peptides, or antibodies to enhance cellular uptake and promote cell specific targeting [46]. Ionis Pharmaceuticals’ ligand-conjugated technology is one example, linking 2′-MOE ASOs to triantennary N-acetylgalactosamine for specific targeting of hepatocytes through asialoglycoprotein receptors [172]. Drug delivery can also be improved with nanocarriers such as lipid and polymeric nanoparticles, spherical nucleic acids, DNA nanostructures, lipoplexes, liposomes and exosomes [46,166,167,173,174]. For instance, nanoparticles protect encapsulated siRNAs from endogenous nuclease cleavage and assist in cellular uptake. Aptamer conjugates are another efficient approach to precisely direct oligonucleotide therapeutics [78].

5.2. Complexity of Cancer

All currently approved oligonucleotide therapeutics treat indications caused by mutations in a single gene, either causing dysregulated expression or aberrant splicing patterns. Thus, targeting the affected gene restores expression or corrects splicing patterns, leading to efficient treatments or even cures in some cases. However, cancer is a multifactor disease usually involving multiple genes, and targeting one of them may not be sufficient [175]. This is a problem not only for oligonucleotide therapeutics, but for all targeted treatments. Targeting multiple affected genes simultaneously may provide an interesting new therapeutic avenue [173,174]. Preclinical studies for targeted therapy have already provided evidence that targeting several pathways simultaneously may lead to a promising anti-cancer effect [166,167]. Most oligonucleotide therapeutics in clinical trials target one gene combined with chemotherapy. We note that one of the siRNA phase 1 clinical trials discussed above showed promising outcomes with several high response cases [153]. The drug tested contains two siRNAs targeting different genes (VEGF and KSP), which inhibit blood supply and proliferation of cancer cells at the same time [153]. Combination therapy targeting multiple affected genes may be a feasible approach in the future. Oligonucleotide therapeutics may be especially well suited for combination therapy as the same drug modality can be applied to target multiple cancer drivers at once.

5.3. Drug Interactions

A number of clinical trials investigated the combination of oligonucleotide therapeutics with chemotherapy and reported no significant improvement of drug response and OS. As mentioned in Section 2.1, plasma proteins such as albumin play an important role as carrier for drug delivery and cellular uptake [176]. ASOs are usually modified to increase their half-life and affinity to plasma proteins and nearly all blood circulating PS ASO bind to plasma proteins [177]. In contrast, PNAs and PMOs exhibit lower plasma protein affinity (less than 25%) [178]. Other oligonucleotides such as siRNAs also require albumin transportation [176]. However, the plasma binding affinity of chemotherapeutics is significantly higher, ranging from >90% for carboplatin and paclitaxel to <30% for cyclophosphamide and cytarabine [179]. Thus, it is possible that oligonucleotides compete with chemotherapeutics for plasma protein binding, which may lead to reduced in vivo efficacy of the combination compared to chemotherapeutics alone [180]. Carrier based combination drug delivery systems using water-soluble polymer conjugates, nanoparticles, dendrimers, and liposomes provide advantages over simultaneous delivery in mixtures or sequential delivery of multiple drugs [181]. The use of polymeric nanoparticles for combination delivery of chemotherapeutics and siRNAs has shown some success [39].

6. Conclusions

Oligonucleotide therapeutics for oncology utilize their specific high affinity binding to target abnormally expressed or spliced genes that drive tumorigenesis and cancer progression. Oligonucleotide therapeutics exhibit promising outcomes in preclinical experiments and in some clinical trials. However, limited data are currently available on phase 3 trials. Recent advances in the development of oligonucleotide therapeutics show both improved efficacy and safety profiles, and enable drug delivery to specific cell types. In summary, oligonucleotide therapeutics provide a promising new approach for the treatment of cancer.

Supplementary Materials

The following are available online at https://0-www-mdpi-com.brum.beds.ac.uk/article/10.3390/ijms22073295/s1. Summary of clinical trials of oligonucleotide therapeutics in oncology as of 01/01/2021.

Author Contributions

H.X., R.N.V., and S.D.D. conceived, wrote, and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded via a Rutherford Discovery Fellowship awarded to S.D.D. by the Royal Society Te Apārangi (RDF-UOO1802), and a Catalyst: Seeding grant awarded to S.D.D. and R.N.V. by the Royal Society Te Apārangi and the New Zealand Ministry of Business, Innovation and Employment (20-UOO-004).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

ASOAntisense Oligonucleotide
PNPhosphoramidate
PSPhosphorothioate
MPMethyl-phosphonate
OSOverall survival
PFSProgression-free survival

References

  1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef]
  2. Stewart, B.W.; Wild, C.P. World Cancer Report 2014; International Agency for Research on Cancer: Lyon, France, 2014. [Google Scholar]
  3. Brill, J.V. Screening for cancer: The economic, medical, and psychosocial issues. Am. J. Manag. Care 2020, 26, S300–S306. [Google Scholar]
  4. Qiao, J.; Liu, Z.; Fu, Y.-X. Adapting conventional cancer treatment for immunotherapy. J. Mol. Med. 2016, 94, 489–495. [Google Scholar] [CrossRef] [PubMed]
  5. Qian, C.-N.; Mei, Y.; Zhang, J. Cancer metastasis: Issues and challenges. Chin. J. Cancer 2017, 36, 38. [Google Scholar] [CrossRef] [PubMed]
  6. Editore, S. Management of Adverse Effects of Radiotherapy; SICS Editore: Milan, Italy, 2014. [Google Scholar]
  7. Schirrmacher, V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int. J. Oncol. 2019, 54, 407–419. [Google Scholar]
  8. Barrueto, L.; Caminero, F.; Cash, L.; Makris, C.; Lamichhane, P.; Deshmukh, R.R. Resistance to Checkpoint Inhibition in Cancer Immunotherapy. Transl. Oncol. 2020, 13, 100738. [Google Scholar] [CrossRef]
  9. Ribas, A.; Hu-Lieskovan, S. What does PD-L1 positive or negative mean? J. Exp. Med. 2016, 213, 2835–2840. [Google Scholar] [CrossRef]
  10. Stoiber, S.; Cadilha, B.L.; Benmebarek, M.-R.; Lesch, S.; Endres, S.; Kobold, S. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. Cells 2019, 8, 472. [Google Scholar] [CrossRef]
  11. Martinez, M.; Moon, E.K. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front. Immunol. 2019, 10, 128. [Google Scholar] [CrossRef] [PubMed]
  12. Hou, B.; Tang, Y.; Li, W.; Zeng, Q.; Chang, D. Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis. Dis. Markers 2019, 2019, 291. [Google Scholar] [CrossRef]
  13. Seebacher, N.A.; Stacy, A.E.; Porter, G.M.; Merlot, A.M. Clinical development of targeted and immune based anti-cancer therapies. J. Exp. Clin. Cancer Res. 2019, 38, 156. [Google Scholar] [CrossRef]
  14. Xie, Y.-H.; Chen, Y.-X.; Fang, J.-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct. Target. Ther. 2020, 5, 22. [Google Scholar] [CrossRef]
  15. Lacouture, M.; Sibaud, V. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Am. J. Clin. Dermatol. 2018, 19, 31–39. [Google Scholar] [CrossRef]
  16. Mehta, M.; Deeksha, D.; Tewari, D.; Gupta, G.; Awasthi, R.; Singh, H.; Pandey, P.; Chellappan, D.K.; Wadhwa, R.; Collet, T.; et al. Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases. Chem. Biol. Interact. 2019, 308, 206–215. [Google Scholar] [CrossRef]
  17. Sun, H.; Zhu, X.; Lu, P.Y.; Rosato, R.R.; Tan, W.; Zu, Y. Oligonucleotide aptamers: New tools for targeted cancer therapy. Mol. Ther. Nucleic Acids 2014, 3, e182. [Google Scholar] [CrossRef] [PubMed]
  18. Wang, T.; Chen, C.; Larcher, L.M.; Barrero, R.A.; Veedu, R.N. Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development. Biotechnol. Adv. 2019, 37, 28–50. [Google Scholar] [CrossRef] [PubMed]
  19. Lipi, F.; Chen, S.; Chakravarthy, M.; Rakesh, S.; Veedu, R.N. In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies. RNA Biol. 2016, 13, 1232–1245. [Google Scholar] [CrossRef] [PubMed]
  20. Aartsma-Rus, A.; Corey, D.R. The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy. Nucleic Acid Ther. 2020, 30, 67–70. [Google Scholar] [CrossRef] [PubMed]
  21. Pescador, R.; Capuzzi, L.; Mantovani, M.; Fulgenzi, A.; Ferrero, M.E. Defibrotide: Properties and clinical use of an old/new drug. Vascul. Pharmacol. 2013, 59, 1–10. [Google Scholar] [CrossRef]
  22. Wan, J.; Bauman, J.A.; Graziewicz, M.A.; Sazani, P.; Kole, R. Oligonucleotide therapeutics in cancer. Cancer Treat. Res. 2013, 158, 213–233. [Google Scholar]
  23. Juliano, R.L.; Carver, K. Cellular uptake and intracellular trafficking of oligonucleotides. Adv. Drug Deliv. Rev. 2015, 87, 35–45. [Google Scholar] [CrossRef] [PubMed]
  24. Juliano, R.L. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016, 44, 6518–6548. [Google Scholar] [CrossRef] [PubMed]
  25. Quemener, A.M.; Bachelot, L.; Forestier, A.; Donnou-Fournet, E.; Gilot, D.; Galibert, M.-D. The powerful world of antisense oligonucleotides: From bench to bedside. Wiley Interdiscip. Rev. RNA 2020, 11, e1594. [Google Scholar] [CrossRef] [PubMed]
  26. Deleavey, G.F.; Damha, M.J. Designing chemically modified oligonucleotides for targeted gene silencing. Chem. Biol. 2012, 19, 937–954. [Google Scholar] [CrossRef]
  27. Dhuri, K.; Bechtold, C.; Quijano, E.; Pham, H.; Gupta, A.; Vikram, A.; Bahal, R. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. J. Clin. Med. Res. 2020, 9, 4. [Google Scholar] [CrossRef]
  28. Thurston, D.E. Chemistry and Pharmacology of Anticancer Drugs; CRC Press: Boca Raton, FL, USA, 2006. [Google Scholar]
  29. Younis, H.S.; Templin, M.; Whiteley, L.O.; Kornbrust, D.; Kim, T.W.; Henry, S.P. Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics. In A Comprehensive Guide to Toxicology in Nonclinical Drug Development; Academic Press: Boston, MA, USA, 2017; pp. 737–754. [Google Scholar]
  30. Crooke, S.T.; Vickers, T.A.; Liang, X.-H. Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res. 2020, 48, 5235–5253. [Google Scholar] [CrossRef]
  31. Le, B.T.; Raguraman, P.; Kosbar, T.R.; Fletcher, S.; Wilton, S.D.; Veedu, R.N. Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics. Mol. Ther. Nucleic Acids 2019, 14, 142–157. [Google Scholar] [CrossRef]
  32. Gaus, H.J.; Gupta, R.; Chappell, A.E.; Østergaard, M.E.; Swayze, E.E.; Seth, P.P. Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay. Nucleic Acids Res. 2019, 47, 1110–1122. [Google Scholar] [CrossRef]
  33. Frazier, K.S. Antisense oligonucleotide therapies: The promise and the challenges from a toxicologic pathologist’s perspective. Toxicol. Pathol. 2015, 43, 78–89. [Google Scholar] [CrossRef]
  34. Krieg, A.M.; Stein, C.A. Phosphorothioate oligodeoxynucleotides: Antisense or anti-protein? Antisense Res. Dev. 1995, 5, 241. [Google Scholar] [CrossRef]
  35. Crooke, S.T.; Wang, S.; Vickers, T.A.; Shen, W.; Liang, X.-H. Cellular uptake and trafficking of antisense oligonucleotides. Nat. Biotechnol. 2017, 35, 230–237. [Google Scholar] [CrossRef]
  36. Miller, C.M.; Harris, E.N. Antisense Oligonucleotides: Treatment Strategies and Cellular Internalization. RNA Dis. 2016, 3, 93. [Google Scholar] [CrossRef]
  37. Faria, M.; Spiller, D.G.; Dubertret, C.; Nelson, J.S.; White, M.R.; Scherman, D.; Hélène, C.; Giovannangeli, C. Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo. Nat. Biotechnol. 2001, 19, 40–44. [Google Scholar] [CrossRef] [PubMed]
  38. Krisztina, P.S.G. Oligonucleotide N3′→P5′ thiophosphoramidates: Synthesis and properties. Tetrahedron Lett. 1999, 40, 7661–7664. [Google Scholar]
  39. Nair, P.R. Delivering Combination Chemotherapies and Targeting Oncogenic Pathways via Polymeric Drug Delivery Systems. Polymers 2019, 11, 630. [Google Scholar] [CrossRef]
  40. Kurreck, J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 2003, 270, 1628–1644. [Google Scholar] [CrossRef]
  41. Pallan, P.S.; Egli, M. Insights into RNA/DNA hybrid recognition and processing by RNase H from the crystal structure of a non-specific enzyme-dsDNA complex. Cell Cycle 2008, 7, 2562–2569. [Google Scholar] [CrossRef] [PubMed]
  42. Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 2002, 133, 467–474. [Google Scholar]
  43. Prakash, T.P.; Kawasaki, A.M.; Wancewicz, E.V.; Shen, L.; Monia, B.P.; Ross, B.S.; Bhat, B.; Manoharan, M. Comparing in vitro and in vivo activity of 2′-O-[2-(methylamino)-2-oxoethyl]- and 2′-O-methoxyethyl-modified antisense oligonucleotides. J. Med. Chem. 2008, 51, 2766–2776. [Google Scholar] [CrossRef]
  44. Sheng, L.; Rigo, F.; Bennett, C.F.; Krainer, A.R.; Hua, Y. Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model. Nucleic Acids Res. 2020, 48, 2853–2865. [Google Scholar] [CrossRef]
  45. Liang, X.-H.; Sun, H.; Nichols, J.G.; Crooke, S.T. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. Mol. Ther. 2017, 25, 2075–2092. [Google Scholar] [CrossRef]
  46. Roberts, T.C.; Langer, R.; Wood, M.J.A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 2020, 19, 673–694. [Google Scholar] [CrossRef]
  47. Khvorova, A.; Watts, J.K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 2017, 35, 238–248. [Google Scholar] [CrossRef]
  48. Braasch, D.A.; Corey, D.R. Locked nucleic acid (LNA): Fine-tuning the recognition of DNA and RNA. Chem. Biol. 2001, 8, 1–7. [Google Scholar] [CrossRef]
  49. Levin, J.D.; Fiala, D.; Samala, M.F.; Kahn, J.D.; Peterson, R.J. Position-dependent effects of locked nucleic acid (LNA) on DNA sequencing and PCR primers. Nucleic Acids Res. 2006, 34, e142. [Google Scholar] [CrossRef]
  50. Iwamoto, N.; Butler, D.C.D.; Svrzikapa, N.; Mohapatra, S.; Zlatev, I.; Sah, D.W.Y.; Meena, D.; Standley, S.M.; Lu, G.; Apponi, L.H.; et al. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat. Biotechnol. 2017, 35, 845–851. [Google Scholar] [CrossRef] [PubMed]
  51. Sardone, V.; Zhou, H.; Muntoni, F.; Ferlini, A.; Falzarano, M.S. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease. Molecules 2017, 22, 563. [Google Scholar] [CrossRef] [PubMed]
  52. Oh, S.Y.; Ju, Y.; Park, H. A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides. Mol. Cells 2009, 28, 341–345. [Google Scholar] [CrossRef]
  53. Debacker, A.J.; Voutila, J.; Catley, M.; Blakey, D.; Habib, N. Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug. Mol. Ther. 2020, 28, 1759–1771. [Google Scholar] [CrossRef] [PubMed]
  54. Xiao, F.; Wei, Z.; Wang, M.; Hoff, A.; Bao, Y.; Tian, L. Oligonucleotide-polymer conjugates: From molecular basics to practical application. Top. Curr. Chem. J. 2020, 378, 24. [Google Scholar] [CrossRef]
  55. Urban-Wojciuk, Z.; Khan, M.M.; Oyler, B.L.; Fåhraeus, R.; Marek-Trzonkowska, N.; Nita-Lazar, A.; Hupp, T.R.; Goodlett, D.R. The Role of TLRs in Anti-cancer Immunity and Tumor Rejection. Front. Immunol. 2019, 10, 2388. [Google Scholar] [CrossRef] [PubMed]
  56. Schleimann, M.H.; Kobberø, M.-L.; Vibholm, L.K.; Kjær, K.; Giron, L.B.; Busman-Sahay, K.; Chan, C.N.; Nekorchuk, M.; Schmidt, M.; Wittig, B.; et al. TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes. EBioMedicine 2019, 45, 328–340. [Google Scholar] [CrossRef]
  57. Kang, T.H.; Mao, C.-P.; Kim, Y.S.; Kim, T.W.; Yang, A.; Lam, B.; Tseng, S.-H.; Farmer, E.; Park, Y.-M.; Hung, C.-F. TLR9 acts as a sensor for tumor-released DNA to modulate anti-tumor immunity after chemotherapy. J. Immunother. Cancer 2019, 7, 260. [Google Scholar] [CrossRef] [PubMed]
  58. Vollmer, J.; Krieg, A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 2009, 61, 195–204. [Google Scholar] [CrossRef] [PubMed]
  59. Hager, S.; Fittler, F.J.; Wagner, E.; Bros, M. Nucleic Acid-Based Approaches for Tumor Therapy. Cells 2020, 9, 61. [Google Scholar] [CrossRef] [PubMed]
  60. Krug, A.; Rothenfusser, S.; Hornung, V.; Jahrsdörfer, B.; Blackwell, S.; Ballas, Z.K.; Endres, S.; Krieg, A.M.; Hartmann, G. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 2001, 31, 2154–2163. [Google Scholar] [CrossRef]
  61. Krieg, A.M.; Yi, A.K.; Matson, S.; Waldschmidt, T.J.; Bishop, G.A.; Teasdale, R.; Koretzky, G.A.; Klinman, D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374, 546–549. [Google Scholar] [CrossRef]
  62. Nehete, P.N.; Williams, L.E.; Chitta, S.; Nehete, B.P.; Patel, A.G.; Ramani, M.D.; Wisniewski, T.; Scholtzova, H. Class C CpG Oligodeoxynucleotide Immunomodulatory Response in Aged Squirrel Monkey. Front. Aging Neurosci. 2020, 12, 36. [Google Scholar] [CrossRef]
  63. Scheiermann, J.; Klinman, D.M. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine 2014, 32, 6377–6389. [Google Scholar] [CrossRef]
  64. Macfarlane, L.-A.; Murphy, P.R. MicroRNA: Biogenesis, Function and Role in Cancer. Curr. Genom. 2010, 11, 537–561. [Google Scholar] [CrossRef] [PubMed]
  65. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509–524. [Google Scholar] [CrossRef]
  66. Hammond, S.M. Dicing and slicing: The core machinery of the RNA interference pathway. FEBS Lett. 2005, 579, 5822–5829. [Google Scholar] [CrossRef] [PubMed]
  67. Peng, Y.; Croce, C.M. The role of MicroRNAs in human cancer. Signal Transduct. Target. Ther. 2016, 1, 15004. [Google Scholar] [CrossRef] [PubMed]
  68. Barbarotto, E.; Schmittgen, T.D.; Calin, G.A. MicroRNAs and cancer: Profile, profile, profile. Int. J. Cancer 2008, 122, 969–977. [Google Scholar] [CrossRef] [PubMed]
  69. Ma, J.; Dong, C.; Ji, C. MicroRNA and drug resistance. Cancer Gene Ther. 2010, 17, 523–531. [Google Scholar] [CrossRef]
  70. Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 2017, 16, 203–222. [Google Scholar] [CrossRef]
  71. Bernstein, E.; Caudy, A.A.; Hammond, S.M.; Hannon, G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409, 363–366. [Google Scholar] [CrossRef]
  72. Mahmoodi, C.G.; Dana, H.; Gharagouzloo, E.; Grijalvo, S.; Eritja, R.; Logsdon, C.D.; Memari, F.; Miri, S.R.; Rad, M.R.; Marmari, V. Small interfering RNAs (siRNAs) in cancer therapy: A nano-based approach. Int. J. Nanomed. 2019, 14, 3111–3128. [Google Scholar] [CrossRef] [PubMed]
  73. Chernikov, I.V.; Vlassov, V.V.; Chernolovskaya, E.L. Current development of siRNA bioconjugates: From research to the clinic. Front. Pharmacol. 2019, 10, 444. [Google Scholar] [CrossRef] [PubMed]
  74. Setten, R.L.; Rossi, J.J.; Han, S.-P. The current state and future directions of RNAi-based therapeutics. Nat. Rev. Drug Discov. 2019, 18, 421–446. [Google Scholar] [CrossRef]
  75. Tatiparti, K.; Sau, S.; Kashaw, S.K.; Iyer, A.K. SiRNA delivery strategies: A comprehensive review of recent developments. Nanomaterials 2017, 7, 77. [Google Scholar] [CrossRef]
  76. Fu, Z.; Xiang, J. Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy. Int. J. Mol. Sci. 2020, 21, 2793. [Google Scholar] [CrossRef] [PubMed]
  77. Pastor, F. Aptamers: A New Technological Platform in Cancer Immunotherapy. Pharmaceuticals 2016, 9, 64. [Google Scholar] [CrossRef]
  78. Han, J.; Gao, L.; Wang, J.; Wang, J. Application and development of aptamer in cancer: From clinical diagnosis to cancer therapy. J. Cancer 2020, 11, 6902–6915. [Google Scholar] [CrossRef] [PubMed]
  79. Kratschmer, C.; Levy, M. Effect of chemical modifications on aptamer stability in serum. Nucleic Acid Ther. 2017, 27, 335–344. [Google Scholar] [CrossRef] [PubMed]
  80. Ni, S.; Yao, H.; Wang, L.; Lu, J.; Jiang, F.; Lu, A.; Zhang, G. Chemical modifications of nucleic acid aptamers for therapeutic purposes. Int. J. Mol. Sci. 2017, 18, 1683. [Google Scholar] [CrossRef] [PubMed]
  81. Kumar, K.P.; Hussain, B.; Yüce, M. Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents. Pharmaceutics 2020, 12, 646. [Google Scholar] [CrossRef] [PubMed]
  82. Morrow, P.K.; Murthy, R.K.; Ensor, J.D.; Gordon, G.S.; Margolin, K.A.; Elias, A.D.; Urba, W.J.; Weng, D.E.; Rugo, H.S.; Hortobagyi, G.N. An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. Cancer 2012, 118, 4098–4104. [Google Scholar] [CrossRef]
  83. Silverman, S.K. Deoxyribozymes: DNA catalysts for bioorganic chemistry. Org. Biomol. Chem. 2004, 2, 2701–2706. [Google Scholar] [CrossRef]
  84. Huo, W.; Li, X.; Wang, B.; Zhang, H.; Zhang, J.; Yang, X.; Jin, Y. Recent advances of DNAzyme-based nanotherapeutic platform in cancer gene therapy. Biophys. Rep. 2020, 123, 1–10. [Google Scholar]
  85. Khachigian, L.M. Deoxyribozymes as Catalytic Nanotherapeutic Agents. Cancer Res. 2019, 79, 879–888. [Google Scholar] [CrossRef] [PubMed]
  86. Zhang, J. RNA-Cleaving DNAzymes: Old Catalysts with New Tricks for Intracellular and In Vivo Applications. Catalysts 2018, 8, 550. [Google Scholar] [CrossRef]
  87. Schubert, S.; Gül, D.C.; Grunert, H.-P.; Zeichhardt, H.; Erdmann, V.A.; Kurreck, J. RNA cleaving “10-23” DNAzymes with enhanced stability and activity. Nucleic Acids Res. 2003, 31, 5982–5992. [Google Scholar] [CrossRef]
  88. Zhou, W.; Ding, J.; Liu, J. Theranostic DNAzymes. Theranostics 2017, 7, 1010–1025. [Google Scholar] [CrossRef] [PubMed]
  89. Thesaurus, N.C.I. C-myb Antisense Oligonucleotide G4460 (Code C1541). Available online: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1541 (accessed on 22 January 2021).
  90. Oh, I.H.; Reddy, E.P. The myb gene family in cell growth, differentiation and apoptosis. Oncogene 1999, 18, 3017–3033. [Google Scholar] [CrossRef] [PubMed]
  91. Fry, E.A.; Inoue, K. c-MYB and DMTF1 in Cancer. Cancer Investig. 2019, 37, 46–65. [Google Scholar] [CrossRef] [PubMed]
  92. Anfossi, G.; Gewirtz, A.M.; Calabretta, B. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc. Natl. Acad. Sci. USA 1989, 86, 3379–3383. [Google Scholar] [CrossRef] [PubMed]
  93. Tondelli, L.; Ricca, A.; Laus, M.; Lelli, M.; Citro, G. Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres. Nucleic Acids Res. 1998, 26, 5425–5431. [Google Scholar] [CrossRef]
  94. Luger, S.M.; O’Brien, S.G.; Ratajczak, J.; Ratajczak, M.Z.; Mick, R.; Stadtmauer, E.A.; Nowell, P.C.; Goldman, J.M.; Gewirtz, A.M. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: A pilot study. Blood 2002, 99, 1150–1158. [Google Scholar] [CrossRef]
  95. Oblimersen, A. BCL-2 antisense oligonucleotide-Genta, G 3139, GC 3139, oblimersen sodium. Drugs R. 2007, 8, 321–334. [Google Scholar]
  96. Harris, M.H.; Thompson, C.B. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 2000, 7, 1182–1191. [Google Scholar] [CrossRef]
  97. Campbell, K.J.; Tait, S.W.G. Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 2018, 8, 8. [Google Scholar] [CrossRef]
  98. Frenzel, A.; Grespi, F.; Chmelewskij, W.; Villunger, A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 2009, 14, 584–596. [Google Scholar] [CrossRef]
  99. O’Brien, S.; Moore, J.O.; Boyd, T.E.; Larratt, L.M.; Skotnicki, A.; Koziner, B.; Chanan-Khan, A.A.; Seymour, J.F.; Gregory, B.R.; Pavletic, S.; et al. Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J. Clin. Oncol. 2007, 25, 1114–1120. [Google Scholar] [CrossRef]
  100. Tolcher, A.W.; Rodrigueza, W.V.; Rasco, D.W.; Patnaik, A.; Papadopoulos, K.P.; Amaya, A.; Moore, T.D.; Gaylor, S.K.; Bisgaier, C.L.; Sooch, M.P.; et al. A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2014, 73, 363–371. [Google Scholar] [CrossRef] [PubMed]
  101. Harb, W.; Lakhani, N.J.; Logsdon, A.; Steigelman, M.; Smith-Green, H.; Woolliscroft, S.G.; Rodrigueza, W.V.; Sooch, M.P.; Messmann, R.A.; Al-Katib, A.M. Pharmacokinetics of the BCL2-targeted DNA interference (DNAi) nanoparticle PNT2258 in patients with recurrent or refractory non-Hodgkin lymphoma. J. Clin. Oncol. 2014, 32, 2586. [Google Scholar] [CrossRef]
  102. Dürig, J.; Dührsen, U.; Klein-Hitpass, L.; Worm, J.; Hansen, J.B.R.; Ørum, H.; Wissenbach, M. The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia 2011, 25, 638–647. [Google Scholar] [CrossRef]
  103. Pollyea, D.A.; Amaya, M.; Strati, P.; Konopleva, M.Y. Venetoclax for AML: Changing the treatment paradigm. Blood Adv. 2019, 3, 4326–4335. [Google Scholar] [CrossRef] [PubMed]
  104. D’Aguanno, S.; Del Bufalo, D. Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells 2020, 9, 1287. [Google Scholar] [CrossRef]
  105. Lahn, M.; Köhler, G.; Sundell, K.; Su, C.; Li, S.; Paterson, B.M.; Bumol, T.F. Protein kinase C alpha expression in breast and ovarian cancer. Oncology 2004, 67, 1–10. [Google Scholar] [CrossRef]
  106. Kazanietz, M.G. Protein Kinase C in Cancer Signaling and Therapy; Springer Science & Business Media: Berlin/Heidelberg, Germany, 2010. [Google Scholar]
  107. Pham, T.N.D.; Perez, W.B.E.; Zhao, H.; Mortazavi, F.; Tonetti, D.A. Protein kinase C α enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin. BMC Cancer 2017, 17, 832. [Google Scholar] [CrossRef]
  108. Roychowdhury, D.; Lahn, M. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): Potential role in breast cancer. Semin. Oncol. 2003, 30, 30–33. [Google Scholar] [CrossRef]
  109. Villalona-Calero, M.A.; Ritch, P.; Figueroa, J.A.; Otterson, G.A.; Belt, R.; Dow, E.; George, S.; Leonardo, J.; McCachren, S.; Miller, G.L.; et al. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 2004, 10, 6086–6093. [Google Scholar] [CrossRef]
  110. Paz-Ares, L.; Douillard, J.-Y.; Koralewski, P.; Manegold, C.; Smit, E.F.; Reyes, J.M.; Chang, G.-C.; John, W.J.; Peterson, P.M.; Obasaju, C.K.; et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2006, 24, 1428–1434. [Google Scholar] [CrossRef] [PubMed]
  111. Lynch, T.J. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report. Am. Soc. Clin. Oncol. 2003, 22, 623. [Google Scholar]
  112. Haque, S.; Morris, J.C. Transforming growth factor-β: A therapeutic target for cancer. Hum. Vaccin. Immunother. 2017, 13, 1741–1750. [Google Scholar] [CrossRef] [PubMed]
  113. Schlingensiepen, K.-H.; Jaschinski, F.; Lang, S.A.; Moser, C.; Geissler, E.K.; Schlitt, H.J.; Kielmanowicz, M.; Schneider, A. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 2011, 102, 1193–1200. [Google Scholar] [CrossRef] [PubMed]
  114. Schlingensiepen, K.-H.; Schlingensiepen, R.; Steinbrecher, A.; Hau, P.; Bogdahn, U.; Fischer-Blass, B.; Jachimczak, P. Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 2006, 17, 129–139. [Google Scholar] [CrossRef]
  115. Vallières, L. Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2. Drugs 2009, 12, 445–453. [Google Scholar]
  116. Hau, P.; Jachimczak, P.; Schlingensiepen, R.; Schulmeyer, F.; Jauch, T.; Steinbrecher, A.; Brawanski, A.; Proescholdt, M.; Schlaier, J.; Buchroithner, J.; et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I/II studies. Oligonucleotides 2007, 17, 201–212. [Google Scholar] [CrossRef]
  117. Hau, P.; Jachimczak, P.; Bogdahn, U. Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides. Expert Rev. Anticancer Ther. 2009, 9, 1663–1674. [Google Scholar] [CrossRef]
  118. Bogdahn, U.; Hau, P.; Stockhammer, G.; Venkataramana, N.K.; Mahapatra, A.K.; Suri, A.; Balasubramaniam, A.; Nair, S.; Oliushine, V.; Parfenov, V.; et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: Results of a randomized and controlled phase IIb study. Neuro. Oncol. 2011, 13, 132–142. [Google Scholar] [CrossRef]
  119. The US Food and Drug Administration Trabedersen Orphan Drug Designations and Approvals. Available online: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=286709 (accessed on 23 March 2021).
  120. Trougakos, I.P.; Pawelec, G.; Tzavelas, C.; Ntouroupi, T.; Gonos, E.S. Clusterin/Apolipoprotein J up-regulation after zinc exposure, replicative senescence or differentiation of human haematopoietic cells. Biogerontology 2006, 7, 375–382. [Google Scholar] [CrossRef]
  121. Peng, M.; Deng, J.; Zhou, S.; Tao, T.; Su, Q.; Yang, X.; Yang, X. The role of Clusterin in cancer metastasis. Cancer Manag. Res. 2019, 11, 2405–2414. [Google Scholar] [CrossRef] [PubMed]
  122. Wang, Y.; Wang, X.; Zhao, H.; Liang, B.; Du, Q. Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression. J. Chemother. 2012, 24, 348–357. [Google Scholar] [CrossRef] [PubMed]
  123. Beer, T.M.; Hotte, S.J.; Saad, F.; Alekseev, B.; Matveev, V.; Fléchon, A.; Gravis, G.; Joly, F.; Chi, K.N.; Malik, Z.; et al. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): A randomised, open-label, international, phase 3 trial. Lancet Oncol. 2017, 18, 1532–1542. [Google Scholar]
  124. Saad, F.; Eisenberger, M.A. Management of Castration Resistant Prostate Cancer; Springer: Berlin/Heidelberg, Germany, 2014. [Google Scholar]
  125. Chi, K.N.; Higano, C.S.; Blumenstein, B.; Ferrero, J.-M.; Reeves, J.; Feyerabend, S.; Gravis, G.; Merseburger, A.S.; Stenzl, A.; Bergman, A.M.; et al. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): A phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2017, 18, 473–485. [Google Scholar] [CrossRef]
  126. Abbas, R.; Larisch, S. Targeting XIAP for Promoting Cancer Cell Death-The Story of ARTS and SMAC. Cells 2020, 9, 663. [Google Scholar] [CrossRef] [PubMed]
  127. Lee, F.A.S.; Zee, B.C.-Y.; Cheung, F.Y.; Kwong, P.; Chiang, C.L.; Leung, K.C.; Siu, S.W.K.; Lee, C.; Lai, M.; Kwok, C.; et al. Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC). Am. J. Clin. Oncol. 2016, 39, 609–613. [Google Scholar] [CrossRef]
  128. Kamran, M.Z.; Patil, P.; Gude, R.P. Role of STAT3 in cancer metastasis and translational advances. Biomed Res. Int. 2013, 2013, 421821. [Google Scholar] [CrossRef]
  129. Pham, T.-H.; Park, H.-M.; Kim, J.; Hong, J.T.; Yoon, D.-Y. STAT3 and p53: Dual Target for Cancer Therapy. Biomedicines 2020, 8, 637. [Google Scholar] [CrossRef]
  130. Xu, H.; Tong, X.; Mugundu, G.; Scott, M.L.; Cook, C.; Arfvidsson, C.; Pease, E.; Zhou, D.; Lyne, P.; Al-Huniti, N. Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch. J. Pharmacokinet. Pharmacodyn. 2019, 46, 65–74. [Google Scholar] [CrossRef] [PubMed]
  131. Burel, S.A.; Han, S.-R.; Lee, H.-S.; Norris, D.A.; Lee, B.-S.; Machemer, T.; Park, S.-Y.; Zhou, T.; He, G.; Kim, Y.; et al. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther. 2013, 23, 213–227. [Google Scholar] [CrossRef]
  132. Reilley, M.J.; McCoon, P.; Cook, C.; Lyne, P.; Kurzrock, R.; Kim, Y.; Woessner, R.; Younes, A.; Nemunaitis, J.; Fowler, N.; et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: Results of a phase 1b trial. J. Immunother. Cancer 2018, 6, 119. [Google Scholar] [CrossRef]
  133. Choi, S.-K.; Kam, H.; Kim, K.-Y.; Park, S.I.; Lee, Y.-S. Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment? Cancers 2019, 11, 1195. [Google Scholar] [CrossRef] [PubMed]
  134. Calderwood, S.K.; Sherman, M.Y.; Ciocca, D.R. Heat Shock Proteins in Cancer; Springer Science & Business Media: Berlin/Heidelberg, Germany, 2007; ISBN 9781402064012. [Google Scholar]
  135. Lelj-Garolla, B.; Kumano, M.; Beraldi, E.; Nappi, L.; Rocchi, P.; Ionescu, D.N.; Fazli, L.; Zoubeidi, A.; Gleave, M.E. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. Mol. Cancer Ther. 2015, 14, 1107–1116. [Google Scholar] [CrossRef] [PubMed]
  136. Spigel, D.R.; Shipley, D.L.; Waterhouse, D.M.; Jones, S.F.; Ward, P.J.; Shih, K.C.; Hemphill, B.; McCleod, M.; Whorf, R.C.; Page, R.D.; et al. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial. Oncologist 2019, 24, e1409–e1416. [Google Scholar] [CrossRef]
  137. Yu, E.Y.; Ellard, S.L.; Hotte, S.J.; Gingerich, J.R.; Joshua, A.M.; Gleave, M.E.; Chi, K.N. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Investig. New Drugs 2018, 36, 278–287. [Google Scholar] [CrossRef]
  138. Ko, A.H.; Murphy, P.B.; Peyton, J.D.; Shipley, D.L.; Al-Hazzouri, A.; Rodriguez, F.A.; Womack, M.S.; Xiong, H.Q.; Waterhouse, D.M.; Tempero, M.A.; et al. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist 2017, 22, 1427–1429. [Google Scholar] [CrossRef]
  139. Miroshnichenko, S.K.; Patutina, O.A.; Burakova, E.A.; Chelobanov, B.P.; Fokina, A.A.; Vlassov, V.V.; Altman, S.; Zenkova, M.A.; Stetsenko, D.A. Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties. Proc. Natl. Acad. Sci. USA 2019, 116, 1229–1234. [Google Scholar] [CrossRef]
  140. Zent, C.S.; Smith, B.J.; Ballas, Z.K.; Wooldridge, J.E.; Link, B.K.; Call, T.G.; Shanafelt, T.D.; Bowen, D.A.; Kay, N.E.; Witzig, T.E.; et al. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk. Lymphoma 2012, 53, 211–217. [Google Scholar] [CrossRef]
  141. Manegold, C.; van Zandwijk, N.; Szczesna, A.; Zatloukal, P.; Au, J.S.K.; Blasinska-Morawiec, M.; Serwatowski, P.; Krzakowski, M.; Jassem, J.; Tan, E.H.; et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2012, 23, 72–77. [Google Scholar] [CrossRef] [PubMed]
  142. Hirsh, V.; Paz-Ares, L.; Boyer, M.; Rosell, R.; Middleton, G.; Eberhardt, W.E.E.; Szczesna, A.; Reiterer, P.; Saleh, M.; Arrieta, O.; et al. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 2011, 29, 2667–2674. [Google Scholar] [CrossRef] [PubMed]
  143. Weber, J.S.; Zarour, H.; Redman, B.; Trefzer, U.; O’Day, S.; van den Eertwegh, A.J.M.; Marshall, E.; Wagner, S. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 2009, 115, 3944–3954. [Google Scholar] [CrossRef]
  144. Ruzsa, A.; Sen, M.; Evans, M.; Lee, L.W.; Hideghety, K.; Rottey, S.; Klimak, P.; Holeckova, P.; Fayette, J.; Csoszi, T.; et al. Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Investig. New Drugs 2014, 32, 1278–1284. [Google Scholar] [CrossRef]
  145. Friedberg, J.W.; Kim, H.; McCauley, M.; Hessel, E.M.; Sims, P.; Fisher, D.C.; Nadler, L.M.; Coffman, R.L.; Freedman, A.S. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: Increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005, 105, 489–495. [Google Scholar] [CrossRef]
  146. Ribas, A.; Medina, T.; Kummar, S.; Amin, A.; Kalbasi, A.; Drabick, J.J.; Barve, M.; Daniels, G.A.; Wong, D.J.; Schmidt, E.V.; et al. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discov. 2018, 8, 1250–1257. [Google Scholar] [CrossRef] [PubMed]
  147. Bonneau, E.; Neveu, B.; Kostantin, E.; Tsongalis, G.J.; De Guire, V. How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. Ejifcc 2019, 30, 114–127. [Google Scholar]
  148. Foss, F.M.; Querfeld, C.; Porcu, P.; Kim, Y.H.; Pacheco, T.; Halwani, A.S.; DeSimone, J.; William, B.M.; Seto, A.G.; Ruckman, J.; et al. Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL). J. Clin. Oncol. 2017, 35, 7564. [Google Scholar] [CrossRef]
  149. Reid, G.; Pel, M.E.; Kirschner, M.B.; Cheng, Y.Y.; Mugridge, N.; Weiss, J.; Williams, M.; Wright, C.; Edelman, J.J.B.; Vallely, M.P.; et al. Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma. Ann. Oncol. 2013, 24, 3128–3135. [Google Scholar] [CrossRef] [PubMed]
  150. van Zandwijk, N.; Pavlakis, N.; Kao, S.C.; Linton, A.; Boyer, M.J.; Clarke, S.; Huynh, Y.; Chrzanowska, A.; Fulham, M.J.; Bailey, D.L.; et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017, 18, 1386–1396. [Google Scholar] [CrossRef]
  151. Varghese, A.M.; Ang, C.; Dimaio, C.J.; Javle, M.M.; Gutierrez, M.; Yarom, N.; Stemmer, S.M.; Golan, T.; Geva, R.; Semenisty, V.; et al. A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT). J. Clin. Orthod. 2020, 38, 4672. [Google Scholar] [CrossRef]
  152. Golan, T.; Khvalevsky, E.Z.; Hubert, A.; Gabai, R.M.; Hen, N.; Segal, A.; Domb, A.; Harari, G.; David, E.B.; Raskin, S.; et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget 2015, 6, 24560–24570. [Google Scholar] [CrossRef]
  153. Tabernero, J.; Shapiro, G.I.; LoRusso, P.M.; Cervantes, A.; Schwartz, G.K.; Weiss, G.J.; Paz-Ares, L.; Cho, D.C.; Infante, J.R.; Alsina, M.; et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013, 3, 406–417. [Google Scholar] [CrossRef] [PubMed]
  154. Tolcher, A.W.; Papadopoulos, K.P.; Patnaik, A.; Rasco, D.W.; Martinez, D.; Wood, D.L.; Fielman, B.; Sharma, M.; Janisch, L.A.; Brown, B.D. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors. J. Clin. Oncol. 2015, 23, 11006. [Google Scholar] [CrossRef]
  155. Dannull, J.; Haley, N.R.; Archer, G.; Nair, S.; Boczkowski, D.; Harper, M.; De Rosa, N.; Pickett, N.; Mosca, P.J.; Burchette, J.; et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J. Clin. Investig. 2013, 123, 3135–3145. [Google Scholar] [CrossRef] [PubMed]
  156. Rosenberg, J.E.; Bambury, R.M.; Van Allen, E.M.; Drabkin, H.A.; Lara, P.N., Jr.; Harzstark, A.L.; Wagle, N.; Figlin, R.A.; Smith, G.W.; Garraway, L.A.; et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Investig. New Drugs 2014, 32, 178–187. [Google Scholar] [CrossRef]
  157. Steurer, M.; Montillo, M.; Scarfò, L.; Mauro, F.R.; Andel, J.; Wildner, S.; Trentin, L.; Janssens, A.; Burgstaller, S.; Frömming, A.; et al. Olaptesed pegol (NOX-A12) with bendamustine and rituximab: A phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica 2019, 104, 2053–2060. [Google Scholar] [CrossRef]
  158. Hoellenriegel, J.; Zboralski, D.; Maasch, C.; Rosin, N.Y.; Wierda, W.G.; Keating, M.J.; Kruschinski, A.; Burger, J.A. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 2014, 123, 1032–1039. [Google Scholar] [CrossRef]
  159. Liao, W.-H.; Yang, L.-F.; Liu, X.-Y.; Zhou, G.-F.; Jiang, W.-Z.; Hou, B.-L.; Sun, L.-Q.; Cao, Y.; Wang, X.-Y. DCE-MRI assessment of the effect of Epstein-Barr virus-encoded latent membrane protein-1 targeted DNAzyme on tumor vasculature in patients with nasopharyngeal carcinomas. BMC Cancer 2014, 14, 835. [Google Scholar] [CrossRef]
  160. Cho, E.-A.; Moloney, F.J.; Cai, H.; Au-Yeung, A.; China, C.; Scolyer, R.A.; Yosufi, B.; Raftery, M.J.; Deng, J.Z.; Morton, S.W.; et al. Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: A phase 1 first-in-human trial (DISCOVER). Lancet 2013, 381, 1835–1843. [Google Scholar] [CrossRef]
  161. Dou, Y.; Jiang, X.; Xie, H.; He, J.; Xiao, S. The Jun N-terminal kinases signaling pathway plays a “seesaw” role in ovarian carcinoma: A molecular aspect. J. Ovarian Res. 2019, 12, 99. [Google Scholar] [CrossRef] [PubMed]
  162. Fokina, A.A.; Stetsenko, D.A.; François, J.-C. DNA enzymes as potential therapeutics: Towards clinical application of 10-23 DNAzymes. Expert Opin. Biol. Ther. 2015, 15, 689–711. [Google Scholar] [CrossRef]
  163. Willett, C.G.; Chang, D.T.; Czito, B.G.; Meyer, J.; Wo, J. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61–70. [Google Scholar]
  164. Dang, C.V.; Reddy, E.P.; Shokat, K.M.; Soucek, L. Drugging the “undruggable” cancer targets. Nat. Rev. Cancer 2017, 17, 502–508. [Google Scholar] [CrossRef]
  165. Krichevsky, A.M.; Uhlmann, E.J. Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond. Neurotherapeutics 2019, 16, 319–347. [Google Scholar] [CrossRef] [PubMed]
  166. Milella, M.; Estrov, Z.; Kornblau, S.M.; Carter, B.Z.; Konopleva, M.; Tari, A.; Schober, W.D.; Harris, D.; Leysath, C.E.; Lopez-Berestein, G.; et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 2002, 99, 3461–3464. [Google Scholar] [CrossRef]
  167. Elez, R.; Piiper, A.; Kronenberger, B.; Kock, M.; Brendel, M.; Hermann, E.; Pliquett, U.; Neumann, E.; Zeuzem, S. Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 2003, 22, 69–80. [Google Scholar] [CrossRef]
  168. Sharma, V.K.; Watts, J.K. Oligonucleotide therapeutics: Chemistry, delivery and clinical progress. Future Med. Chem. 2015, 7, 2221–2242. [Google Scholar] [CrossRef]
  169. Lam, J.K.W.; Chow, M.Y.T.; Zhang, Y.; Leung, S.W.S. siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol. Ther. Nucleic Acids 2015, 4, e252. [Google Scholar] [CrossRef]
  170. The US FDA Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics (accessed on 23 March 2021).
  171. Gandara, D.; Narayan, S.; Lara, P.N., Jr.; Goldberg, Z.; Davies, A.; Lau, D.H.M.; Mack, P.; Gumerlock, P.; Vijayakumar, S. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin. Cancer Res. 2005, 11, 5057s–5062s. [Google Scholar] [CrossRef]
  172. Crooke, S.T.; Baker, B.F.; Xia, S.; Yu, R.Z.; Viney, N.J.; Wang, Y.; Tsimikas, S.; Geary, R.S. Integrated Assessment of the Clinical Performance of GalNAc-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience. Nucleic Acid Ther. 2019, 29, 16–32. [Google Scholar] [CrossRef]
  173. Richard, M.J.; John, H.C. Designing Multi-Target Drugs; Royal Society of Chemistry: London, UK, 2012; ISBN 9781849734912. [Google Scholar]
  174. Xie, L.; Bourne, P.E. Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem. Front. Pharmacol. 2015, 6, 209. [Google Scholar] [CrossRef]
  175. Adjiri, A. DNA Mutations May Not Be the Cause of Cancer. Oncol. Ther. 2017, 5, 85–101. [Google Scholar] [CrossRef] [PubMed]
  176. Hoogenboezem, E.N.; Duvall, C.L. Harnessing albumin as a carrier for cancer therapies. Adv. Drug Deliv. Rev. 2018, 130, 73–89. [Google Scholar] [CrossRef]
  177. Bijsterbosch, M.K.; Rump, E.T.; De Vrueh, R.L.; Dorland, R.; van Veghel, R.; Tivel, K.L.; Biessen, E.A.; van Berkel, T.J.; Manoharan, M. Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res. 2000, 28, 2717–2725. [Google Scholar] [CrossRef]
  178. Kilanowska, A.; Studzińska, S. In vivo and in vitro studies of antisense oligonucleotides–a review. RSC Adv. 2020, 10, 34501–34516. [Google Scholar] [CrossRef]
  179. Sparreboom, A.; Loos, W.J. Protein binding of anticancer drugs. In Handbook of Anticancer Pharmacokinetics and Pharmacodynamics; Springer: Berlin/Heidelberg, Germany, 2004; pp. 169–188. [Google Scholar]
  180. Schneider, E.K.; Huang, J.X.; Carbone, V.; Baker, M.; Azad, M.A.K.; Cooper, M.A.; Li, J.; Velkov, T. Drug-drug plasma protein binding interactions of ivacaftor. J. Mol. Recognit. 2015, 28, 339–348. [Google Scholar] [CrossRef]
  181. Lee, J.H.; Nan, A. Combination drug delivery approaches in metastatic breast cancer. J. Drug Deliv. 2012, 2012, 915375. [Google Scholar] [CrossRef] [PubMed]
Ijms 22 03295 g001 550
Figure 1. Summary of clinical trials for oligonucleotide therapeutics in oncology. (a) Numbers of trials for different types of oligonucleotide therapeutics; (b) Trials status. Number of trials were retrieved from Supplementary Materials.
Figure 1. Summary of clinical trials for oligonucleotide therapeutics in oncology. (a) Numbers of trials for different types of oligonucleotide therapeutics; (b) Trials status. Number of trials were retrieved from Supplementary Materials.
Ijms 22 03295 g001
Ijms 22 03295 g002 550
Figure 2. Summary of mechanisms of different types of oligonucleotide therapeutics. ASOs inhibit protein expression by sterically blocking translation (A) or RNase H dependent RNA degradation (B), or alter splicing (C); siRNAs degrade mRNA through RISC (D); miR mimetics degrade mRNA through RISC (E); antagomiRs block endogenous miRNA (F); DNAzymes specifically bind and cleave RNA (G); aptamers block cell receptors (H), block interactions between proteins (I), or act as drug delivery vectors (J). RISC, RNA-induced silencing complex. ASOs, aptamers and DNAzymes can also be delivered through vectors and cell endocytosis (not shown in the figure). Figure created with BioRender.com. Adapted from https://app.biorender.com/biorender-templates (accessed on 15 March 2021).
Figure 2. Summary of mechanisms of different types of oligonucleotide therapeutics. ASOs inhibit protein expression by sterically blocking translation (A) or RNase H dependent RNA degradation (B), or alter splicing (C); siRNAs degrade mRNA through RISC (D); miR mimetics degrade mRNA through RISC (E); antagomiRs block endogenous miRNA (F); DNAzymes specifically bind and cleave RNA (G); aptamers block cell receptors (H), block interactions between proteins (I), or act as drug delivery vectors (J). RISC, RNA-induced silencing complex. ASOs, aptamers and DNAzymes can also be delivered through vectors and cell endocytosis (not shown in the figure). Figure created with BioRender.com. Adapted from https://app.biorender.com/biorender-templates (accessed on 15 March 2021).
Ijms 22 03295 g002
Ijms 22 03295 g003 550
Figure 3. Overview of different chemical modification of antisense oligonucleotides.
Figure 3. Overview of different chemical modification of antisense oligonucleotides.
Ijms 22 03295 g003
Table
Table 1. Summary of currently approved oligonucleotide therapeutics.
Table 1. Summary of currently approved oligonucleotide therapeutics.
Drug NamesMarket NamesCompaniesFDA ApprovedIndicationsDrug ModalityMechanismsTargets
fomivirsenVitraveneIonis Pharmaceuticals, Novartis1998Cytomegalovirus (CMV) retinitisASO Translation blockCMV protein IE2
pegaptanibMacugenOSI Pharmaceuticals2004Neovascular age-related macular degenerationAptamerBinding and blockingHeparin-binding domain of VEGF-165
mipomersenKynamroKastle Therapeutics, Ionis Pharmaceuticals, Genzyme2013Homozygous familial hypercholesterolemiaASO RNase H degradationApolipoprotein B100
eteplirsenExondys 51Sarepta Therapeutics2016Duchenne muscular dystrophyASO Splicing modulationExon 51 of DMD
nusinersenSpinrazaIonis Pharmaceuticals, Biogen2016Spinal muscular atrophyASO Splicing modulationExon 7 of SMN2
defibrotideDefitelioJazz Pharmaceuticals2016Veno-occlusive disease in liverAptamerBinding and activatingAdenosine A1/A2 receptor
inotersenTegsediAkcea Therapeutics2018Polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosisASO RNase H degradationTransthyretin
milasenNot applicableBoston Children’s Hospital2018Mila Makovec’s CLN7 gene associated with Batten diseaseASO Splicing modulationCLN7
patisiranOnpattroAlnylam2018Polyneuropathy caused by hATTR amyloidosissiRNARNAiTransthyretin
golodirsenVyondys 53Sarepta Therapeutics2019Duchenne muscular dystrophyASO Splicing modulationExon 53 of DMD
givosiranGivlaariAlnylam2019Acute hepatic porphyria (AHP)siRNARNAi5-aminolevulinic acid synthase
volanesorsenWaylivraAkcea TherapeuticsEMA approved in 2019 1Familial chylomicronemia syndrome (FCS)ASORNase H degradationApolipoprotein C3
viltolarsenViltepsoNS Pharma2020Duchenne muscular dystrophyASO Splicing modulationExon 53 of DMD
casimersenAmondys 45Sarepta Therapeutics2021Duchenne muscular dystrophyASO Splicing modulationExon 45 of DMD
1 Volanesorsen did not receive FDA approval in 2018 but was approved by European Medicines Agency (EMA) in 2019.
Table
Table 2. Summary of current oligonucleotide therapeutics in clinical trials for oncology.
Table 2. Summary of current oligonucleotide therapeutics in clinical trials for oncology.
Oligonucleotide TherapeuticsTargetDrug ModalityCancer TypesClinical Trials
DNAzyme targeting EBV-LMP1 (DZ1)EBV-LMP1DNAzymeNasopharyngeal CancerNCT01449942
68Ga-Sgc8PTK7aptamerColorectal CancerNCT03385148
EYE001 (Anti-VEGF Pegylated Aptamer) VEGFaptamerRetinal CancerNCT00056199
NOX-A12CXCL12aptamerPancreatic Cancer|Colorectal Cancer|Myeloma|LeukemiaNCT01521533|NCT01521533|NCT03168139
AS1411NCLaptamerAcute Myeloid LeukemiaNCT01034410|NCT00881244|NCT00740441|NCT00512083
KRAS G12D siRNAKRASG12DsiRNAPancreatic CancerNCT03608631
EphA2-targeting DOPC-encapsulated siRNAEPHA2siRNASolid TumorsNCT01591356
APN401CBLBsiRNABrain Cancer|Melanoma|Pancreatic Cancer|Renal Cell CancerNCT03087591|NCT02166255
Proteasome siRNA and tumor antigen RNA-transfected dendritic cellsLMP2, LMP7, MECL1siRNAMelanomaNCT00672542
TKM-080301PLK1siRNACancer with hepatic metastases| Liver Cancer|Hepatocellular Cancer| Adrenocortical CancerNCT01437007|NCT02191878|NCT01262235
Atu027PNK3siRNASolid Tumors|Pancreatic CancerNCT00938574|NCT01808638
DCR-MYCMYCsiRNASolid Tumors|Hepatocellular CancerNCT02110563|NCT02314052
CALAA-01M2 subunit of ribonucleotide reductase (R2)siRNASolid TumorsNCT00689065
siG12D LODERKRASG12DsiRNAPancreatic CancerNCT01676259|NCT01188785
ARO-HIF2HIF2AsiRNAClear Cell Renal Cell CarcinomaNCT04169711
SV40 vectors carrying siRNAUnknownsiRNAChronic Myeloid LeukemiaNCT00257647
MRX34 30 unique oncogenes, including but not limited to MET, MYC, PDGFRA, CDK4/6 and BCL2miRNALiver Cancer|Lung Cancer |Lymphoma |Melanoma|Multiple Myeloma|Renal Cell Cancer|NCT01829971|NCT02862145
INT-1B3 JNK1miRNASolid TumorNCT04675996
TargomiRs Multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3AmiRNAMalignant Pleural Mesothelioma|Non-Small Cell Lung CancerNCT02369198
Cobomarsen (MRG-106)MIR155miRNACutaneous T-Cell Lymphoma|Lymphoma|LeukemiaNCT03837457|NCT03713320|NCT02580552
1018 ISSTLR9ASONon-Hodgkin’s Lymphoma|Colorectal CancerNCT00251394|NCT00403052
AEG35156XIAPASOHepatocellular Cancer|Pancreatic Cancer|Breast Cancer|Non-Small Cell Lung Cancer| Leukemia|LymphomaNCT00357747|NCT00363974|NCT00372736|NCT00385775|NCT00557596|NCT00558545|NCT00558922|NCT00768339|NCT00882869|NCT01018069
Apatorsen (OGX-427)HSP27ASOUrologic Cancer|Bladder Cancer|Prostate Cancer|Urothelial Cancer|Non-Small Cell Lung CancerNCT00487786|NCT01454089|NCT01681433|NCT01780545|NCT01829113
ARRx (AZD5312)ARASOProstate CancerNCT02144051|NCT03300505
AZD4785KRASASONon-Small Cell Lung CancerNCT03101839
AZD8701FOXP3ASOAdvanced CancerNCT04504669
AZD9150STAT3ASOBladder Cancer|Lymphoma|MalignanciesNCT02546661|NCT02549651|NCT03394144|NCT03527147|NCT03819465
BP1001GRB2ASOPh1 Positive Leukemia|Acute Myeloid Leukemia|Chronic Myelogenous LeukemiaNCT01159028|NCT02781883|NCT02923986|NCT04196257
Cenersen (EL625)TP53ASOAcute Myelogenous Leukemia|LymphomaNCT00074737|NCT00636155|NCT00967512|NCT02243124
CpG 7909 (PF03512676) TLR9ASOMelanoma|Breast Cancer|Renal Cancer|Lymphoma|Non-Small Cell Lung Cancer|Esophageal Cancer|Prostate CancerNCT00031278|NCT00040950|NCT00043368|NCT00043394|NCT00043407|NCT00043420|NCT00070629|NCT00070642|NCT00085189|NCT00112242|NCT00145145|NCT00185965|NCT00199836|NCT00226993|NCT00233506|NCT00292045|NCT00299728|NCT00369291|NCT00438880|NCT00471471|NCT00490529|NCT00669292|NCT00819806|NCT00824733|NCT00880581|NCT01266603|NCT01588015
CpG ODN (GNKG168)TLR9ASOLeukemiaNCT01035216|NCT01743807
CpG Oligonucleotide 1TLR9ASOBreast CancerNCT00640861
CpG-ODN 1TLR9ASOGlioblastomaNCT00190424
Custirsen (OGX-011)ApoJASOProstate Cancer|Breast Cancer|Non-Small Cell Lung CancerNCT00054106|NCT00138658|NCT00138918|NCT00258375|NCT00258388|NCT00327340|NCT00471432|NCT01083615|NCT01188187|NCT01497470|NCT01578655|NCT01630733
Danvatirsen (AZD9150, ISIS STAT3Rx)STAT3ASOAdvanced CancersNCT01563302|NCT01839604|NCT02417753|NCT02417753|NCT02499328|NCT02983578|NCT03334617
EGFR Antisense DNAEGFRASOHead and Neck Squamous Cell Cancer|Gastric Cancer|Ovarian Cancer|Prostate CancerNCT00009841|NCT00023634|NCT00903461|NCT01592721|NCT03433027
EZN-2968 (RO7070179,SPC2968)HIF1AASOHepatocellular Cancer|LymphomaNCT00466583|NCT01120288|NCT02564614|NCT00466583
G4460CMYBASOLeukemia| Hematologic MalignanciesNCT00002592| NCT00780052
IGF-1R/AS ODNIGF1ASOGliomaNCT01550523|NCT02507583
IGV-001 containing autologous GBM cells treated with antisense oligonucleotide (IMV-001)IGF1RASOGlioblastomaNCT04485949
IMO-2055 (EMD 1201081)TLR9ASORenal Cell Cancer|Colorectal Cancer|Non-Small Cell Lung Cancer|Head and Neck CancerNCT00729053|NCT01040832|NCT00633529|NCT00719199|NCT01360827
ION251IRF4ASOMyelomaNCT04398485
ION537YAP1ASOAdvanced Solid TumorsNCT04659096
ISIS 183750(ISIS-EIF4ERx, LY2275796)EIF4EASOCastrate-Resistant Prostate Cancer|Non-Small Cell Lung Cancer|Colorectal CancerNCT00903708|NCT01234025|NCT01234038|NCT01675128
ISIS 2503HRASASOColorectal Cancer|Pancreatic CancerNCT00004193|NCT00005594|NCT00006467
ISIS 5132CRAFASOOvarian CancerNCT00003892
L-Bcl-2 antisense oligonucleotideBCL2ASOAdvanced Lymphoid MalignanciesNCT04072458
LErafAONCRAFASOCancersNCT00024648|NCT00024661|NCT00100672
LucanixTGFB2ASONon-small Cell Lung CancerNCT01058785|NCT01279798
LY2181308BIRC5ASONon-small Cell Lung CancerNCT01107444
LY900003 (ISIS 3521, Affinitak)PKCAASOMelanoma|Lung Cancer|Non-Small Cell Lung Cancer|Breast CancerNCT00003989|NCT00017407|NCT00034268|NCT00042679|NCT00042679|NCT00003236
MTL-CEBPACEBPAASOHepatocellular CancerNCT02716012|NCT04105335|NCT04710641
Oblimersen (G3139)BCL2ASOCancersNCT00003103|NCT00004862|NCT00004870|NCT00005032|NCT00016263|NCT00017251|NCT00017589|NCT00017602|NCT00021749|NCT00024440|NCT00030641|NCT00039117|NCT00039481|NCT00042978|NCT00047229|NCT00049192|NCT00049374|NCT00054548|NCT00054639|NCT00055822|NCT00059813|NCT00060112|NCT00062244|NCT00063934|NCT00064259|NCT00070083|NCT00070343|NCT00078234|NCT00079131|NCT00080847|NCT00085124|NCT00085228|NCT00086944|NCT00091078|NCT00301795|NCT00409383|NCT00517218|NCT00518895|NCT00542893|NCT00543205|NCT00543231|NCT00636545|NCT00736450|NCT01200342
OGX-427HSP27ASOCancersNCT00487786|NCT00959868|NCT01120470|NCT01844817|NCT02423590
PNT2258BCL2ASOProstate Cancer|Lymphoma|MelanomaNCT01191775|NCT01733238|NCT02226965
SPC2996BCL2ASOChronic Lymphocytic LeukemiaNCT00285103
TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) VaccineTGFB2ASOAdvanced CancerNCT00684294
SD-101TLR9ASOCancersNCT01042379|NCT01745354|NCT02254772|NCT02266147|NCT02521870|NCT02731742|NCT02927964|NCT03007732|NCT03322384|NCT03410901|NCT04050085|NCT03831295
Trabedersen (AP 12009, OT-101)TGFB2ASOGlioblastoma|Anaplastic Astrocytoma|Pancreatic Cancer|Melanoma|Colorectal CancerNCT00431561|NCT00761280|NCT00844064
VEGF-Antisense OligonucleotideVEGFASOMesotheliomaNCT00668499
1 as no additional information is available about these two CpG oligonucleotides on ClinicalTrials.gov accessed on 15 March 2021, we treat them as two different CpG oligonucleotides.
Table
Table 3. ASO chemical modifications and pharmacology profiles.
Table 3. ASO chemical modifications and pharmacology profiles.
ASO ModificationModification TypeNuclease ResistanceRNAse H CleavageTarget AffinityToxicity
Phosphorothioate (PS)Phosphate +Yes-++
Phosphoramidate (NP)Phosphate +No++
Methyl-phosphonate (MP)Phosphate +No-+
2′-O-methyl (2′-OMe)Ribose++No+++
Reduced immune activation; less toxic than PS
2′-O-methoxyethyl (2′-MOE)Ribose++No+++
Reduced immune activation; Less than 2′-OMe; less toxic than PS
Phosphorodiamidate morpholino (PMO)Ribose phosphate ++No++Safer
Locked nucleic acid (LNA)Ribose++No++++++
Constrained ethyl (cEt)Ribose+++No+++++
Peptide nucleic acid (PNA)Ribose phosphate ++No++++
No immune activation
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Xiong, H.; Veedu, R.N.; Diermeier, S.D. Recent Advances in Oligonucleotide Therapeutics in Oncology. Int. J. Mol. Sci. 2021, 22, 3295. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22073295

AMA Style

Xiong H, Veedu RN, Diermeier SD. Recent Advances in Oligonucleotide Therapeutics in Oncology. International Journal of Molecular Sciences. 2021; 22(7):3295. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22073295

Chicago/Turabian Style

Xiong, Haoyu, Rakesh N. Veedu, and Sarah D. Diermeier. 2021. "Recent Advances in Oligonucleotide Therapeutics in Oncology" International Journal of Molecular Sciences 22, no. 7: 3295. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22073295

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop